Upload
others
View
9
Download
0
Embed Size (px)
Citation preview
1
RAPORT DE AUTOEVALUARE
perioada: 1 iulie 2005- 30 iunie 2010
1. Datele de autentificare ale unităţii de cercetare-dezvoltare
1.1. Denumirea: INSTITUTUL ONCOLOGIC “Prof. Dr. I. CHIRICUTA” CLUJ-NAPOCA
1.2. Statutul Juridic1): Unitate Sanitara – Institut cu Personalitate Juridica - INSTITUTUL
ONCOLOGIC “Prof. Dr. I. CHIRICUTA” CLUJ-NAPOCA
1.3. Actul de infiintare2): Hotărârea de Guvern Nr. 144/2010
1.4. Numărul de înregistrare in Registrul potenţialilor contractori:1428
1.5. Manager : Conf.Dr. Alexandru Irimie
1.6. Adresa: Republicii 34-36, CLUJ NAPOCA
1.7. Telefon, fax, pagina web, e-mail: 0264-598361; 0264-598365; www.iocn.ro ,
2. Domeniul de specialitate
2.1. Conform clasificării UNESCO3): 3289
2.2. Conform clasificării CAEN: principal 8610 ; secundar 7310
3. Starea unităţii de cercetare-dezvoltare
3.1. Misiunea unităţii de cercetare-dezvoltare, direcţiile de cercetare, dezvoltare, inovare:
(maximum 1.000 de caractere):
Viziunea noastră este de a contribui substanţial la ameliorarea tratamentelor
oncologice prin integrarea activităţii de cercetare fundamentală aplicativă cu cercetarea şi
practica clinică.
Misiunea Departamentului de cercetare ştiinţifică este de a planifica, proiecta şi pune
în practică strategii menite a asigura un nivel ridicat de performanţă al cercetării ştiinţifice în
Institutul Oncologic “Prof. Dr. Ion Chiricuţă”, în context naţional şi internaţional.
Direcţiile principale de acţiune ale Departamentului de cercetare ştiinţifică sunt:
a. promovarea excelenţei în cercetare;
2
b. modernizarea şi eficientizarea bazei materiale a cercetării ştiinţifice din Institut
c. orientarea cercetării din Institutul Oncologic “Prof. Dr. Ion Chiricuţă” spre
nevoile pe termen mediu şi lung ale specialităţilor medicale implicate în
tratamentul cancerului şi pe un plan mai general ale societăţii noastre.
d. realizarea unui management eficient şi eficace al activităţii de cercetare
ştiinţifică
e. întărirea dimensiunii cooperării internaţionale
f. crearea unui climat de încredere şi cooperare ştiinţifică între cercetătorii IOCN
cadrele didactice ale UMF Cluj care lucrează cu integrare clinică în Institut,
ceilalţi specialişti, bazat pe transparenţă decizională
g. dimensiunea educaţională: atragerea de cercetători tineri şi formarea acestora
pentru a deveni competitivi pe plan naţional şi internaţional
h. evaluarea periodică a rezultatelor cercetării ştiinţifice şi a centrelor de cercetare
ştiinţifică existente în Institut.
Aceste direcţii de acţiune au în vedere creşterea relevanţei cercetării ştiinţifice în Institutul
Oncologic “Prof. Dr. Ion Chiricuţă”, promovarea acesteia pe plan naţional şi internaţional şi
integrarea cercetării ştiinţifice în aria cercetării europene.
3.2. Modul de valorificare a rezultatelor de cercetare, dezvoltare, inovare si gradul de
recunoaştere a acestora (maximum 1.000 de caractere):
Cercetarea în oncologie are un pronunţat caracter multidisciplinar. Valorificarea rezultatelor
cercetării de laborator este posibilă prin translaţia acestora în practica clinică cu scopul de a
individualiza tratamentele şi de a introduce metode terapeutice noi. Deasemenea cercetarea
clinică (studiile clinice) este cea care validează pe plan practic valoarea diferitelor tratamente.
Institutul este partener la numeroase studii clinice, iar unele dintre aceste sunt iniţiate chiar în
Institut. Ne propunem creşterea progresivă a numărului de pacienţi care sunt trataţi în studii
clinice ca un indicator al performanţei sectorului de cercetare şi creşterea ponderii
cunoştinţelor care să facă obiectul transferului din „laborator la patul bolnavului”.
3
Recunoaşterea acestor rezultate trebuie concretizată prin creşterea numărului de publicaţii în
reviste cotate pe plan naţional şi mai ales internaţional.
3.3. Situaţia financiara - datorii la bugetul de stat:
NU SUNT
4. Criterii primare de performanta
punctaj
4.1. Lucrări ştiinţifice/tehnice publicate in reviste de
specialitate cotate ISI4)
4.1.1. Număr de lucrări ştiinţifice 84 x 30 =2520
4.1.2. Punctaj cumulat ISI5) 324.714 x 5= 1623.57
4.1.3. Număr de citări in reviste de specialitate cotate ISI6) 4031x 5 = 20155
(Lista lucrărilor si citărilor, grupate pe ani, se ataşează ca anexa nr. 4.1)
Total punctaj cap. 4.1: 24298.57
4.2. Brevete de inventie7)
4.2.1. Număr de brevete x 30
4.2.2. Număr de citări de brevete in sistemul ISI x 5
(Lista brevetelor si citărilor, grupate pe ani, se ataşează ca anexa nr. 4.2)
Total punctaj cap. 4.2: 0
4.3. Produse si tehnologii rezultate din activitati de cercetare, bazate pe brevete, omologări
sau inovaţii proprii. Studii prospective si tehnologice si servicii rezultate din activitatea de
cercetare-dezvoltare, comandate de beneficiar
(Se indica contractul si firma care utilizează produsul, serviciul si tehnologia).
4.3.1. Număr de produse, tehnologii, studii, servicii 11 x 20 = 220
(Lista produselor, serviciilor si tehnologiilor, grupate pe ani, se ataşează
ca anexa nr. 4.3)
Total punctaj cap. 4.3: 220
Total punctaj cap. 4: 24518.57
4
5. Criterii secundare de performanta
5.1. Lucrări ştiinţifice (tehnice) publicate in reviste de specialitate8)
fără cotaţie ISI
5.1.1. Număr de lucrări 41 x 5 = 205
(Lista lucrărilor grupate pe ani se ataşează ca anexa nr. 5.1)
Total punctaj cap. 5.1:
5.2. Lucrări ştiinţifice prezentate la conferinţe internaţionale cu comitet de program
5.2.1. Număr de comunicări prezentate 159 x 5 =795
(Lista comunicărilor grupate pe ani se ataşează ca anexa nr. 5.2)
Total punctaj cap. 5.2:
5.3. Modele fizice, modele experimentale, modele funcţionale, prototipuri,normative,
proceduri, metodologii, reglementari si planuri tehnice noi sau perfecţionate, realizate in
cadrul programelor naţionale sau comandate de
beneficiar
5.3.1. Număr de modele, normative, proceduri etc.: 1 x 5 = 5
(Lista modelelor, normativelor etc., grupate pe ani, se ataşează ca anexa nr. 5.3)
Total punctaj cap. 5.3: 5
Total punctaj cap. 5: 205+795+5=1005
6. Prestigiul profesional
6.1. Membri (incluzând statutul de recenzor) in colectivele de redacţie ale unor reviste (cotate
ISI sau incluse in baze de date internaţionale) sau in colective editoriale ale unor edituri
internaţionale recunoscute
Număr de prezente in perioada pentru care se face evaluarea: 5 x 20=100
Nr. crt. Nume Titlul revistei/editurii
6.2. Membri in colectivele de redacţie ale revistelor recunoscute naţional (din categoria B in
clasificarea CNCSIS)
Număr de prezente: 1 x 10=10
5
Nr. crt. Nume Titlul revistei/editurii
6.3. Premii internaţionale obţinute printr-un proces de selecţie
Anexa 6.3
Număr de premii: 7 x 20 = 140
Nr. crt. Nume Premiul Anul
6.4. Premii naţionale ale Academiei Romane
Număr de premii: x 20
Nr. crt. Nume Premiul Anul
6.5. Conducători de doctorat, membri ai unităţii de cercetare
Număr de conducători de doctorat: x 10
Nr. crt. Nume
6.6. Număr de doctori in ştiinţa, membri ai unităţii de cercetare
Număr de doctori in ştiinţa: 10 x 10 = 100
Total punctaj cap. 6:100+10+140+100=350
Total punctaj cap. 4+5+6: 24518.57+1005+350=25873.57
7. Venituri realizate prin contracte de cercetare in domeniul pentru care se face evaluarea (in
perioada pentru care se face evaluarea):
7.1. Numărul si valoarea contractelor de cercetare internaţionale finanţate din fonduri
publice9):
7.2. Numărul si valoarea contractelor de cercetare internaţionale finanţate din fonduri
private:
7.3. Numărul si valoarea contractelor de cercetare naţionale finanţate din fonduri publice10):
an Nr.
proiecte
tip program Valoare in
RON pe an
Valoare
totala RON
pe an
Valoare
totala in
EUR pe an
2005 8 1 - grant
4 – CEEX VIASAN
3 -PNCD I VIASAN
2.000
167.500
229.960
399.460
114.131,43
6
2006 27 2 granturi
22 CEEX VIASAN, CNMP
3 PNCD I VIASAN
69.000
1265.828
188.880
1.523.708
435.345,14
2007 34 1 PNCD II CNCSIS
23 CEEX
3 PNCD I VIASAN
7 PNCD II – Pr 4
99.000
2103.892
136.880
303.185
2.642.957
755.130,57
2008 35 1 PNCD II CNCSIS
17 CEEX
3 PNCD I VIASAN
14 PNCD II – PR IV
374.000
3.099.308
75.000
1.174.327
4.722.635 1.185.043,4
1
2009 16 2 PNCD II CNCSIS
14 PNCD II – PR IV
288.221
701.806
990.027
234.148,57
TOTAL 10.278.787,0
0
2.723.799,1
2
7.4. Numărul si valoarea contractelor de cercetare naţionale finanţate din fonduri private:
7.5. Alte surse:
7 bis. Venituri realizate din activităţi economice (servicii, microproducţie):
8. Resursa umana de cercetare
8.1. Total personal de cercetare care realizează venituri din activitatea de cercetare-
dezvoltare/din care doctori in ştiinţa:
8.1.1. Cercetători ştiinţifici gradul 1 (profesori)/din care doctori in ştiinţa: 3/3
8.1.2. Cercetători ştiinţifici gradul 2 (conferenţiari)/din care doctori in ştiinţa: 6/6
8.1.3. Cercetători ştiinţifici gradul 3 (lectori)/din care doctori in ştiinţa: 1/1
8.1.4. Cercetători ştiinţifici/din care doctori in ştiinţa: 3/0
8.1.5. Asistenţi de cercetare: 4/1
8.1.6. Total personal auxiliar de cercetare angajat: 18
7
8.2. Date privind perfecţionarea resursei umane
8.2.1. Număr de doctoranzi si masteranzi care lucrează in unitatea de cercetare-dezvoltare la
data completării formularului: 8
8.2.2. Număr de teze de doctorat realizate in unitatea de cercetare-dezvoltare in perioada
pentru care se face evaluarea:13
9. Infrastructura de cercetare-dezvoltare
9.1. Laboratoare de cercetare-dezvoltare:
ORGANIGRAMA IN ANEXA
9.2. Lista echipamentelor performante achiziţionate in ultimii 10 ani:
Nr. crt. Echipamentul Anul fabricaţiei Valoarea Sursa de finanţare a investiţiei
Nr.
crt.
Echipament Anul
achiziţionării
Valoarea Sursa de
finanţare a
investiţiei
1 Sistem HPLC 2001 155.905,72 Grant Banca
Mondiala UMF
(custodie IOCN)
2 Secventiator automat 2001 140.335,1 Grant Banca
Mondiala UMF
(custodie IOCN)
3 Centrifuga de laborator 2001 10.153,83 Grant Banca
Mondiala UMF
(custodie IOCN)
4 Procesor Vysis VP2000 2001 69.277 Grant Banca
Mondiala UMF
(custodie IOCN)
5 Analizator de imagini pt
electr.
2001 45.116,23 Grant Banca
Mondiala UMF
8
(custodie IOCN)
6 Spectrofotometru UV cu db 2001 40.497,66 Grant Banca
Mondiala UMF
(custodie IOCN)
7 Sistem imobilizare 2001 3.937,59 Grant Banca
Mondiala UMF
(custodie IOCN)
8 Celula de transfer pt statting 2001 18.839,24 Grant Banca
UMF (custodie
IOCN)Mondiala
9 Instalatie de Electroforeza
medicala
2001 43.439,01 Grant Banca
Mondiala UMF
(custodie IOCN)
10 Sistem de analiza automata 2001 203.062,02 Grant Banca
Mondiala UMF
(custodie IOCN)
11 Centrifuga universala cu
acces
2001 48.563,54 Grant Banca
Mondiala UMF
(custodie IOCN)
12 Hota in flux laminar 2001 16.691,33 Grant Banca
Mondiala UMF
(custodie IOCN)
13 Sistem de analiza a imaginii 2002 141.937,72 Grant Banca
Mondiala UMF
(custodie IOCN)
14 Sistem Electroforeza 2002 71.232,75 Grant Banca
Mondiala UMF
(custodie IOCN)
15 Sistem pt microfotografiere 2002 76.893,60 Grant Banca
9
Mondiala UMF
(custodie IOCN)
16 Microscop E 1000 Nikon 2002 134.563,8 Grant Banca
Mondiala UMF
(custodie IOCN)
17 Hota HH 1-2 Plus 2002 16.843,01 Grant Banca
Mondiala UMF
(custodie IOCN)
18 Incubator 2002 14.393,87 Grant Banca
Mondiala UMF
(custodie IOCN)
19 Cititor Elisa cu spalator 2002 23.748,81 Grant Banca
Mondiala UMF
(custodie IOCN)
20 Analizor de citometrie cu
acces...
2003 184.725,41 Chelt generale
universitare UMF
(custodie IOCN)
21 Masa chirurgicala cu acesorii 2005 64.092,21 Cercetare MEC
22 Trusa chirurgie laparoscopica 2005 150.854,16 Cercetare MEC
23 Monitor pacient MEC 1000 2005 11.109 Cercetare MEC
24 Monitor pacient MEC 1000 2005 11.109 Cercetare MEC
25 Monitor pacient MEC 1000 2005 11.109 Cercetare MEC
26 Sistem PCR 96 WELL 2006 21.658 Cercetare MEC
27 Hota bacteriologica Lamil
Plus 16
2006 23.389,45 Cercetare MEC
28 Upgrade sistem de stocare si
transmisie imagini
2006 27.000 Cercetare MEC
29 Incubator cu CO2 2006 32.487 Cercetare MEC
30 Incubator cu CO2 2006 23.431,5 Cercetare MEC
10
31 Spectrofotometru UV VIS
(sistem analiza nanodrop)
2006 27.908,48 Cercetare MEC
32 Centrifuga Universal 320R cu
racire
2006 23.211,79 Cercetare MEC
33 Hota bacteriologica lamil plus
10
2006 21.967,40 Cercetare MEC
34 Omogenizator (procesor ) cu
ultrasunete
2006 12.560,10 Cercetare MEC
35 Aparat fabricat fulgi de
gheata
2007 11426 CNCSIS
36 Criocauter cu acesorii 2007 22.201,83 Cercetare MEC
37 Electrocauter MBC 600 2007 21.082,27 Cercetare MEC
38 Electrocauter seria 78377 2007 20.675,31 Cercetare MEC
39 Statie includere la parafina 2007 31.502,16 Cercetare MEC
40 Aparat de produs gheata
Ziegra
2007 14.489,62 Cercetare MEC
41 Aparat maruntit probe
biologice seria 30208
2007 8.658,44 Cercetare MEC
42 Ultracongelator vertical 440 l,
-86 0 C
2007 30.675,23 Cercetare MEC
43 Vas Dewar azot lichid - rack 2007 16.842,37 Cercetare MEC
44 Vas Dewar azot lichid 2007 9.991,49 Cercetare MEC
45 Traductor endocavitar EC123 2007 27.728,19 Cercetare MEC
46 Balanta analitica cu 5
zecimale si incinta cantarire
2007 10.549,35 Cercetare MEC
47 Hota cu flux laminar Lamil
Plus
2007 22.530,98 Cercetare MEC
48 Aparat foto digital Olympus
E330
2007 15.670 Cercetare MEC
11
49 Dulap rack black 19 ” 2007 17.600 Cercetare MEC
50 Microscop inversat config
completa
2007 170.635,29 Cercetare MEC
51 Separator de celule 2007 8.093,74 Cercetare MEC
52 Vas Dewar 10 l 2007 3.690,73 Cercetare MEC
53 Microtom RM 2125 2007 21.227,42 Cercetare MEC
54 Microtom RM 2125 2007 21.227,42 Cercetare MEC
55 Statie de lucru GROSSLAB SR 2007 66.000 Cercetare MEC
56 Centrifuga cu racire
MIKRO200R
2007 10.438,68 Cercetare MEC
57 Electroporator 2007 18.772,25 Cercetare MEC
58
Microscop pt.analize
histologice 2007 14.385,67
Cercetare MEC
59
Sistem siguranta Back-up
CO2 2007 5.287,17
Cercetare MEC
60 Autostainer 2007 162.292,53 Cercetare MEC
61
Sursa de lumina pt.lupe
operatorii 2007 6.506,85
Cercetare MEC
62 Hota de culturi clasa a II-a 2007 17.600,85 Cercetare MEC
63 Etuva de laborator - pupinel 2007 3.803,24 Cercetare MEC
64 Camera foto NIKON 2007 6.479,55 Cercetare MEC
65 Lupe operatorii 2007 7.282,80 Cercetare MEC
66 Infusomat FMS 2007 5.569,20 Cercetare MEC
67 Centrifuga cu racire 2007 14.137,20 Cercetare MEC
68 Placa sofanta 2007 2.817,09 Cercetare MEC
69 Balanta analitica cu 5 zec. 2007 3.516,39 Cercetare MEC
70 Hota laminara 2007 12.643,94 Cercetare MEC
71 Dozimetru personal digital 2007 6.479,55 Cercetare MEC
12
72 Microscop inversat motorizat 2007 170.635,29 Cercetare MEC
73 Cititor de microplaci 2008 135.656,43 Cercetare MEC
74
Geldoc XR System (Sistem de
analiza western blott) 2008 45.993,50
Cercetare MEC
75
Sistem de electroforeza si
Western Blotting 2008 16.303,00
Cercetare MEC
76 Placa sofanta 2008 6.892,88 Cercetare MEC
77
Disp.pt.tehnica Tisuue
microassay 2008 8.496,60
Cercetare MEC
78 Detector de ozon 2008 39.680,55 Cercetare MEC
79 Procesor tesuturi 2008 124.937,92 Cercetare MEC
80 Incubator de culturi celulare 2008 17.635,80 Cercetare MEC
81
Instalatie de purificare a
aerului 2008 45.941,14
Cercetare MEC
82 Hota cu flux laminar cls. II 2008 44.510,28 Cercetare MEC
83
Placa de baza pt.fix.pacient +
accesorii 2008 21.935,27
Cercetare MEC
84 LAMPA BACTERICIDA 60 PL 2008 3.000,00 Cercetare MEC
85 Centrifuga cu racire 2008 37.213,68 Cercetare MEC
86 Procesor de tesuturi 2008 62786.32 Cercetare MEC
87 Hota de culturi cls.II 2008 7.259,00 Cercetare MEC
88 Lightcycler 2008 185.640,00 Cercetare MEC
89 Lampa scialitica cu satelit 2008 41.888,00 Cercetare MEC
90
Instalatie de purificare a
aerului pentru indepartarea
speciilor de ozon active 2008 91.882,28
Cercetare MEC
91
Upgrade Microscop Zeiss
Axio Observer 2008 99.305,50
Cercetare MEC
13
92 Pistol de prelevare biopsii 2008 9.282,00 Cercetare MEC
93 Ecograf Acuson X 300 2008 104.779,50 Cercetare MEC
94
Sistem de upgradare
centrifuga Universal 32 R 2008 3.857,98
Cercetare MEC
95 Analozor lightcycler 2008 185.640,00 Cercetare MEC
96 UV/Metru 2009 7.199,50 Cercetare MEC
97
Lampa cercetare cu
ultraviolete 2009 6.985,30
Cercetare MEC
98 Tije politron 2009 46.652,76 CNCSIS
99 UV/Metru 2009 7.199,50 Cercetare MEC
100
Lampa cercetare cu
ultraviolete 2009 6.985,30
Cercetare MEC
101
Locator 4110 litri cu sistem
de role portabile 2009 31.319,26
Cercetare MEC
102 Platforma microarray 2007 145.000 Cercetare MEC
___________ 1) Se mentioneaza forma de organizare si persoana juridica: daca unitatea de cercetare-
dezvoltare nu are personalitate juridica, se mentioneaza denumirea institutiei cu
personalitate juridica care o reprezinta (de exemplu, Centrul de ............... din cadrul
Universitatii ...............). 2) Se mentioneaza titlul actului, data emiterii, organul emitent si, dupa caz, modificarile
ulterioare
3) Domeniile de clasificare UNESCO pot fi accesate la www.mct.ro/ancs.
4) Indexate de Thomson Scientific [fost Institute for Scientific Information (ISI) in Science
Citation Index Expanded, Social Sciences Citation Index sau Arts & Humanities Citation Index].
5) Punctajul ISI se obtine prin insumarea factorilor de impact ai publicatiilor respective.
Factorii de impact pot fi accesati la www.cimec.org.ar.
6) Sunt excluse autocitarile.
14
7) Se specifica daca brevetul este national/international (USPTO, EPO, JPO) si numarul
brevetului.
8) In cazul revistelor romanesti, sunt luate in considerare cele cotate CNCSIS, categoria B (vezi
www.cncsis.ro).
9) Valori defalcate pe ani si valoarea totala in euro.
10) Datele vor fi prezentate pe tipuri de programe (PNCDI, CEEX, granturi etc.); valorile
contractelor vor fi defalcate pe ani.
Reprezentant legal
Institutul Oncologic “Prof Dr I.Chiricuta”
Manager
Conf.Dr.Alexandru Irimie
Director cercetare - dezvoltare
Sef lucrari . Dr. Ioana Neagoe
15
ANEXA 4.1
Lucrari stiintifice/tehnice publicate in reviste de specialitate cotate ISI4)
84X 30 = 2520 ;
Punctaj cumulat ISI 324.714 x 5= 1623.57 ;
Citari – 4031 X 5 = 20.155
Total= 24298.57
2005
1. I.D. Postescu, C. Tatomir, G.Chereches, I.Brie, G .Damian , D.Petrisor, A.M.Hosu,
N.Pop: Spectroscopic characterisation of grape extracts with potential role in tumor
growth inhibition, J. Optoel. Adv. Materials (JOAM), 9, 564-567, 2007 (ISI-2005,
impact factor 1.138) citari 6
2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S,
Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay
B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L; National Cancer
Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-
cell lung cancer. N Engl J Med. 2005 Jul 14;353(2):123-32.PMID: 16014882 Factor de
impact 2005 - 44,016
3. Eniu A, Palmieri FM, Perez EA. Weekly administration of docetaxel and paclitaxel in
metastatic or advanced breast cancer. Oncologist. 2005 Oct;10(9):665-85.
Review.PMID: 16249346 Factor de impact 2005 3,962
4. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J,
Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K. Gefitinib plus best
supportive care in previously treated patients with refractory advanced non-small-
cell lung cancer: results from a randomised, placebo-controlled, multicentre study
16
(Iressa Survival Evaluation in Lung Cancer). Lancet. 2005 Oct 29-Nov
4;366(9496):1527-37.PMID: 16257339 Factor de impact 23,4
2006
5. - R.Cosnarovici, Şt. Neamţu, E.Mihuţ, D.Cernea, N.Todor, Luciana Neamţiu, The
benefit of high dose methotrexate terapy in childhood, Pediatric Blood & Cancer,
47,4, pp.443-444 Factor de impact 1,882
6. Veronique Winnepenninckx, Vladimir Lazar, Stefan Micheils, Philippe Dessen,
Marguerite Stas, Soledad R. Alonso, Marie-Franoise Avril, Pablo L. Ortiz Romero,
Thomas Robert, Ovidiu Balacescu, Alexander M.M. Eggremont, Gilbert Lenoir, Alain
Sarasin, Thomas Tursz, Joost J. van den Oord, Alain Spatz. On behalf of the Melanoma
Group of the European Organization for Research and Treatment of Cancer. Gene
expression profiling of primary cutaneous melanoma and clinical outcome. J Natl
Cancer Inst, 2006 apr 5, 98 (7): 472-82.factor de impact 15,271 nr de citari -106 in
sistem Google Scholar
7. Dorhoi, V. Dobrean, M. Zahan, P. Virag. Modulatory effects of several herbal
extracts on avian peripheral blood cell immune responses, Phytotherapy Research,
factor de impact 0, 508, 2006, 20(5): 352-358. John Wiley & Sons
8. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Franklin WA, Dziadziuszko R, Thatcher N,
Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Watkins C, Flannery A, Ellison
G, Donald E, Knight L, Parums D, Botwood N, Holloway B. Molecular predictors of
outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-
cell lung cancer. J Clin Oncol. 2006 Nov 1;24(31):5034-42.PMID: 17075123 Factor de
impact 1.376
17
9. Eniu A, Carlson RW, Aziz Z, Bines J, Hortobágyi GN, Bese NS, Love RR, Vikram B,
Kurkure A, Anderson BO; Global Summit Treatment and Allocation of Resources
Panel. Breast cancer in limited-resource countries: treatment and allocation of
resources Breast J. 2006 Jan-Feb;12 Suppl 1:S38-53.PMID: 16430398 Factor de
impact 1,61
10. Benjamin O. Anderson, MD*, Roman Shyyan, MD † , Alexandru Eniu, MD ‡ , Robert A.
Smith, PhD § , Cheng-Har Yip, MD ¶ , Nuran Senel Bese, MD # , Louis W. C. Chow, MD ^
, Shahla Masood, MD € , Scott D. Ramsey, MD, PhD ¢ , and Robert W. Carlson, MD**
*University of Washington, Seattle, Washington; † Lviv Cancer Center, Lviv, Ukraine; ‡ Cancer Institute I. Chiricuta, Cluj-Napoca, Romania; § American Cancer Society,
Atlanta, Georgia; ¶ University of Malaya Medical Center, Kuala Lumpur, Malaysia; #
Cerrahpasa Medical School, Istanbul, Turkey; ^ University of Hong Kong Medical
Center, Pokfulam, Hong Kong; €University of Florida, Jacksonville, Florida; ¢ Fred
Hutchinson Cancer Research Center, Seattle, Washington; and **Stanford
University, Stanford, California Breast Cancer in Limited-Resource Countries: An
Overview of the Breast Health Global Initiative 2005 Guidelines The Breast Journal
2006 Volume 12 Issue s1, Pages S3 - S15 Published Online: 16 Jan 2006 Factor de
impact 1,61
11. Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N, Ciuleanu T,
Cucevic B, Gyurkovits K, Ulsperger E, Jassem J, Grgic M, Saip P, Szilasi M, Wiltschke C,
Wagnerova M, Oskina N, Soldatenkova V, Zielinski C, Wenczl M; Central European
Cooperative Oncology Group CECOG. Cisplatin and gemcitabine first-line
chemotherapy followed by maintenance gemcitabine or best supportive care in
advanced non-small cell lung cancer: a phase III trial. Lung Cancer. 2006
May;52(2):155-63. Epub 2006 Mar 29.PMID: 16569462 Factor de impact 3.554
18
12. Cucuianu A, Patiu M, Rusu A. Hepcidin and multiple myeloma related anemia.
Medical Hypotheses, ISSN 0306-9877, 66:352-354, 2006 – idexat ISI – IF=1.393
2007
13. Daria Cosaceanu, Mia Carapancea, Oana Alexandru, Raluca Budiu, Hanna-
Stianmartinsson, Maria Starborg, Maria Vrabete, Lena Kanter, Rolf Lewensohn, Anica
Dricu. Comparison of three approaches for inhibiting insulin-like growth factor I
receptor and their effects on NSCLC cell lines in vitro. Growth Factors; 2007, 25 (1): 1-
8. factor de impact – 3,95
14. D Cosaceanu, RA Budiu, M Carapaceanu, J Castro, R Lewensohn, A Dricu. Ionizing
radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-
DNA binding modulating Ku86 expression via p38 kinase-dependent mechanism.
Oncogene, 2007. 26, 2423-2434 factor de impact- 6,582
15. Carapancea M, Cosaceanu D, Budiu R, Kwiecinska A, Tataranu L, Ciubotaru V,
Alexandru O, Banita M, Pisoschi C, Backlund ML, Lewensohn R, Dricu A. Dual
targeting of IGF-1R and PDGFR inhibits proliferation in high-grade gliomas cells and
induces radiosensitivity in JNK-1 expressing cells. Neurooncol. 2007 Dec;85(3):245-
54. Epub 2007 Jun 14 factor de impact – 1,84
16. Radulescu D, Pripon S, Ciuleanu TE, Radulescu LI. Malignant primary pulmonary
tumor with hemangiopericytoma-like features: conventional hemangiopericytoma
versus solitary fibrous tumor. Clin Lung Cancer. 2007 Sep;8(8):504-8.PMID: 17922977
Factor de impact - 2,39
19
17. Radulescu D, Pripon S, Parv A, Duncea C, Ciuleanu TE. Altered left ventricular
diastolic performance in oncologic patients treated with epirubicin.Congest Heart
Fail. 2007 Jul-Aug;13(4):215-20.PMID: 17673874 Factor de impact 2007 – 3,6
18. Grigorescu A, Ciuleanu T, Firoiu E, Muresan DR, Teodorescu G, Basson BR. A
randomized phase II trial of sequential gemcitabine plus vinorelbine followed by
gemcitabine plus ifosfamide versus gemcitabine plus cisplatin in the treatment of
chemo-naive patients with stages III and IV non-small cell lung cancer (NSCLC). Lung
Cancer. 2007 Aug;57(2):168-74. Epub 2007 Apr 30.PMID: 17467848 Factor de impact
2007 – 3,455
19. I.D. Postescu, C. Tatomir, G. Cherecheş, I. Brie, G. Damian, D. Petrişor, A-M Hosu, V.
Miclăuş, A. Pop: Spectroscopic characterization of some grape extracts with potential
role in tumor growth inhibition, Journal of Optoelectronics and Advanced Materials,
2007, 9(3), 564-567, Factor de impact 0.577.
2008
20. Langer CJ, O'Byrne KJ, Socinski MA, Mikhailov SM, Leśniewski-Kmak K, Smakal M,
Ciuleanu TE, Orlov SV, Dediu M, Heigener D, Eisenfeld AJ, Sandalic L, Oldham FB,
Singer JW, Ross HJ. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in
combination with carboplatin versus standard paclitaxel and carboplatin in the
treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung
cancer. J Thorac Oncol. 2008 Jun;3(6):623-30.PMID: 18520802 [PubMed - indexed for
MEDLINE]Related citations Factor de impact 2008 – 4,547
21. Smith RE Jr, Aapro MS, Ludwig H, Pintér T, Smakal M, Ciuleanu TE, Chen L, Lillie T,
Glaspy JA. Darbepoetin alpha for the treatment of anemia in patients with active
cancer not receiving chemotherapy or radiotherapy: results of a phase III,
multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol. 2008
20
Mar 1;26(7):1040-50. Epub 2008 Jan 28.PMID: 18227526 Factor de impact 2006 -
13.598
22. Eniu A, Carlson RW, El Saghir NS, Bines J, Bese NS, Vorobiof D, Masetti R, Anderson
BO; Breast Health Global Initiative Treatment Panel. Guideline implementation for
breast healthcare in low- and middle-income countries: treatment resource
allocation. Cancer. 2008 Oct 15;113(8 Suppl):2269-81.PMID: 18837019 Factor de
impact 5,418
23. El Saghir NS, Eniu A, Carlson RW, Aziz Z, Vorobiof D, Hortobagyi GN; Breast Health
Global Initiative Systemic Therapy Focus Group. Locally advanced breast cancer:
treatment guideline implementation with particular attention to low- and middle-
income countries. Cancer. 2008 Oct 15;113(8 Suppl):2315-24.PMID: 18837023 Factor
de impact 5,418
24. Masood S, Vass L, Ibarra JA Jr, Ljung BM, Stalsberg H, Eniu A, Carlson RW, Anderson
BO; Breast Health Global Initiative Pathology Focus Group. Breast pathology
guideline implementation in low- and middle-income countries. Cancer. 2008 Oct
15;113(8 Suppl):2297-304.PMID: 18837021 Factor de impact 5,418
25. Bines J, Eniu A. Effective but cost-prohibitive drugs in breast cancer treatment: a
clinician's perspective. Cancer. 2008 Oct 15;113(8 Suppl):2353-8. Review.PMID:
18837028 Factor de impact 5,418
26. Dima D, Trifa AP, Cucuianu A, Popp RA, Patiu M, Petrov L. Monitoring T315I mutation
in chronic myeloid leukemia by amplification refractory mutation system PCR. Rom
Rev Lab Med. 2008, 13,4:17-20 – indexat ISI - IF=0
21
27. Patiu M., Laszlo G., Cucuianu A.: Feritins in iron metabolism investigation. Revista
Romana de Medicina de Laborator.vol 11 nr 2 iunie 2008 pag 53-55 indexat ISI – IF = 0
28. S.Suciu, I.D. Postescu, A. Mureşan, P. Virág, D. Daicoviciu, E. Fischer-Fodor. In vitro
and in vivo Studies on the Modulatory Effects of a Grape (Vitis vinifera) Seed Extract,
J. Clin. Biochem. Nutr., 2008, Suppl. 43, 493-96, i.f. 0.312.
29. E.Fischer-Fodor, N. Moldovan, P. Virág, O. Soriţău, I. Brie, P. Lonnecke, E. Hey-
Hawkins, L. Silaghi Dumitrescu: The CellScan Technology for In Vitro Studies on Novel
Platinum Complexes with Organoarsenic Ligands, Dalton Transactions, 2008, 6393-
6400, i.f. 3.58.
30. T.Dicu, I. Brie, P. Virág, E. Fischer, M. Perde, V. Foriş, V. Cernea, C. Cosma.
Genotoxic effects of 60Co γ-rays on Chinese hamster ovary (CHO) cells, Nukleonika,
2008, 53 (4), 161-165, i.f. 0.267.
31. A.Filip, S. Clichici, A. Mureşan, D. Daicoviciu, C. Tatomir, C. Login, S. Dreve, C.
Gherman: Effects of PDT with 5-aminolevulinic acid and chitosan on Walker
Carcinosarcoma. Exp. Oncol., 2008, 30, 3, 212-219, i.f. 0.115.
2009
32. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I,
Begbie S, Tzekova V, Cucevic B, Pereira JR, Yang SH, Madhavan J, Sugarman KP,
Peterson P, John WJ, Krejcy K, Belani CP. Maintenance pemetrexed plus best
supportive care versus placebo plus best supportive care for non-small-cell lung
22
cancer: a randomised, double-blind, phase 3 study. Lancet. 2009 Oct
24;374(9699):1432-40. Epub 2009 Sep 18.PMID: 19767093 Factor de impact 30,758
33. Socinski MA, Smit EF, Lorigan P, Konduri K, Reck M, Szczesna A, Blakely J,
Serwatowski P, Karaseva NA, Ciuleanu T, Jassem J, Dediu M, Hong S, Visseren-Grul C,
Hanauske AR, Obasaju CK, Guba SC, Thatcher N. Phase III study of pemetrexed plus
carboplatin compared with etoposide plus carboplatin in chemotherapy-naive
patients with extensive-stage small-cell lung cancer. J Clin Oncol. 2009 Oct
1;27(28):4787-92. Epub 2009 Aug 31.PMID: 19720897Factor de impact 13.598
34. Gatzemeier U, Ciuleanu T, Dediu M, Ganea-Motan E, Lubenau H, Del Giglio A. XM02,
the first biosimilar G-CSF, is safe and effective in reducing the duration of severe
neutropenia and incidence of febrile neutropenia in patients with small cell or non-
small cell lung cancer receiving platinum-based chemotherapy. J Thorac Oncol. 2009
Jun;4(6):736-40.PMID: 19404210 Factor de impact 4,547
35. Le Péchoux C, Dunant A, Senan S, Wolfson A, Quoix E, Faivre-Finn C, Ciuleanu T,
Arriagada R, Jones R, Wanders R, Lerouge D, Laplanche A; Prophylactic Cranial
Irradiation (PCI) Collaborative Group. Standard-dose versus higher-dose prophylactic
cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in
complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01,
EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet
Oncol. 2009 May;10(5):467-74. Epub 2009 Apr 20.PMID: 19386548 Factor de impact
10.119
36. Ciuleanu TE, Pavlovsky AV, Bodoky G, Garin AM, Langmuir VK, Kroll S, Tidmarsh GT. A
randomised Phase III trial of glufosfamide compared with best supportive care in
metastatic pancreatic adenocarcinoma previously treated with gemcitabine. Eur J
23
Cancer. 2009 Jun;45(9):1589-96. Epub 2009 Jan 31.PMID: 19188061 Factor de
impact 4.167
37. O Tudoran. I Berindan Neagoe, O Balacescu, E Dronca, C. Burz, L Balacescu, I
Nedelea, Al. Irimie, O. Popescu, Al Irimie, V. Cristea. Evaluation of tumor
angiogenesis through VEGF modulkation in ovarian cancer in vitro using RNA
interference. Romanian Biotechnological Letters, 2009 vol 14, no.4, 4560-4566. ISI
factor impact 0.152
38. Burz C, Berindan-Neagoe IB, Balacescu O, Tanaselia C, Ursu M, Gog A, Vlase L,
Chintoanu M, Balacescu L, Leucuta SE, Irimie A, Cristea V. Clinical and
pharmacokinetics study of oxaliplatin in colon cancer patients. J Gastrointestin Liver
Dis. 2009 Mar;18(1):39-43. 1 citare in Google Scholar. FI=1.265
39. Burz C, Berindan-Neagoe I, Balacescu O, Irimie A. Apoptosis in cancer: Key
molecular signaling pathways and therapy targets. Acta Oncol. 2009 Jun 9:1-11. ISI,
Factor de impact (2008): 2.739 nr de citari -8 in sistem Google Scholar.
40. Vlad AM, Budiu RA, Lenzner DE, Wang Y, Thaller JA, Colonello K, Crowley-Nowick PA,
Kelley JL, Price FV, Edwards RP. A phase II trial of intraperitoneal interleukin-2 in
patients with platinum-resistant or platinum-refractory ovarian cancer. Cancer
Immunol Immunother. 2009 Aug 19. [Epub ahead of print]. ISI, Factor de impact
(2009): 3.791
41. Budiu RA, Diaconu I, Chrissluis R, Dricu A, Edwards RP, Vlad AM. Dis Model Mech. A
conditional mouse model for human MUC1-positive endometriosis shows the
presence of anti-MUC1 antibodies and Foxp3+ regulatory T cells. Dis Model Mech.
24
2009 Nov-Dec;2(11-12):593-603. Epub 2009 Oct 19. ISI, Factor de impact (2009):
3.304
42. Nicula FA. Suteu O. Pais R. Neamtiu L. Description of the national situation of
cervical cancer screening in the member states of the European Union. Eur J Cancer
2009;45:2685-2708. Factor de impact 4,121
43. Ronco G. Balegooijen M. Becker N. Chil A. Fender M. Giubilato P. Kurtinaitis J.
Lancucki L. Lynge E. Morais A. O’Reilly M. Sparen P. Suteu O. Rebolj M. Veerus P.
Primic Zakelj M. Anttila A. Process performance of cervical screenning programmes in
Europe. Eur J. Cancer, 2009;45:2659-2670. Factor de impact 4,121
44. Anttila A. Von Karsa L. Aasmaa A. Fender M. Patnick J. Rebolj M. Nicula F. Vass
L.Valerianova Z. Voti L. Sauvaget C. Ronco G. Cervical cancer screening policies and
coverage in Europe. Eur J Cancer 2009; 45:2649-2658. Factor de impact 4,121
45. Nicula F. A. Anttila A. Neamtiu L. Primic Zachelj M. Tachezy R. Chill A. Grce M. Kesic
V. Challenges in starting organised screening programmes for cervical cancer in the
new member states of the European Union. Eur J Cancer 2009; 45: 2679-2684.
Factor de impact 4,121
46. Neamţiu L. A Medical Resources Allocation Problem. Results in Mathematics.
Birkhauser Verlag Basel/ Swizerland, 53(2009), p. 341-348. Factor de impact 0,513
47. Buzas C, Sparchez Z, Cucuianu A, Manole S, Lupescu I, Acalovschi M. Budd-Chiari
syndrome secondary to polycythemia vera. A case report. J Gastrointest Liver Dis,
2009, 18(3):363-6 – indexat ISI – IF=1.265
25
48. Trifa AP, Popp RA, Cucuianu A, Dima D, Militaru MS, Patiu M, Pop IV. JAK2 p.V617F
mutation - tetra-primer PCR and PCR-RFLP comparative semiquantitative approaches
for estimation of the mutant allele in myeloproliferative neoplasms. Rom Rev Lab
Med. 2009, 14,1:23-36 – indexat ISI – IF=0
49. P.Virág, I. Brie, I.D. Postescu, M. Perde-Schrepler, E. Fischer-Fodor, O. Soriţău, A.
Irimie, V. Cernea. Comparative study of two evaluation methods for the genotoxic
effects of environmental heavy metals on normal cells, Toxicol. Ind. Health, 25 (4-5),
2009, 253-8, i.f. 0.700.
50. A. Filip, S. Clichici, D. Daicoviciu, A.Mureşan, I. D. Postescu, M. Perde- Schrepler, D.
Olteanu: Photochemoprevention of cutaneous neoplasia through natural products,
Exp. Oncol., ISSN 0204-3564, 2009 Mar; 31(1), 9-15, i.f. 0.115.
51. T. Dicu, I. D. Postescu, V. Foriş, I. Brie, E. Fischer-Fodor, M. Moldovan, C. Cosma:
The effect of a grape seed extract on radiation-induced DNA damage in human
lymphocytes, Amer. Inst. Phys. Conf. Proceed., 2009, 1131, 181-187.
52. M. C. Mihu, D. Rus Ciucă, O. Soriţău, S. Susman, D. Mihu: Isolation and
characterization of mezenchymal stem cells from the amniotic membrane, Romanian
Journal of Morphology and Embryology, 2009; 50(1):73-77.
53. M. Lukáč, M. Mrva, E. Fischer-Fodor, I. Lacko, M. Bukovský, N. Miklášová, F.
Ondriska, F. Devínsky : Synthesis and biological activity of dialkylphosphocholines
Elsevier, Bioorganic & Medicinal Chemistry Letters 19, 2009, 6346-6349, i.f. 2.531.
54. N. Miklášová, E. Fischer-Fodor, P. Lonnecke, M. Perde Schrepler, P. Virág, C.
Tatomir, V. I. Cernea, E. Hey-Hawkins, L. Silaghi- Dumitrescu: Antiproliferative effect
26
and genotoxicity of novel synthesized palladium complexes with organoarsenic
ligands, J. Inorg. Biochem., 2009, 103, 1739-1747, i.f. 3.133.
55. C. Tomuleasa, S. Şuşman, O. Soriţău, V. Foriş, E. Páll, C. Mihu: Primum non nocere.
Is stem cell research ready for clinical trials?, Journal of Euroepan Medical Students’
Association on Medical and Scientific Affairs JEMSA, 2009, 34-38.
56. C. Tomuleasa, V. Foris, O. Soriţău, E. Páll, E. Fischer-Fodor, V. Lung-Illes, I. Brie,
P.Virág, M. Perde-Schrepler, I. D. Postescu, G. Cherecheş, O. Bărbos, C. Tatomir.
Effects of 60Co gamma-rays on human osteoprogenitor cells.Rom J Morphol
Embryol 2009; 50(3):349-55.
57. O. Lucaciu, M. Băciuţ, G. Băciuţ, D. Gheban, S. Bran, M. Hedeşiu, C. Nicola, O.
Soriţău, D. Gui: Bone Regeneration in Craniofacial Reconstruction with Particulate
Grafts Obtained Through Tissue Engineering. Particulate Science and Technology An
International Journal, 2009 ; 27, 6 , 497–518, ISSN- 0272-6351, i.f. 0.417.
58. A. Mureşan, Ş. Suciu, S. Ghibu, D. Daicoviciu, I. D. Postescu, I. Login: Antioxidant
effects of polyphenols in experimental hypobaric hypoxia, Bull. USAMV, 2009, 66(1),
160-164 (revistă ISI din 2009). ISSN-1454-2382.
59. Seicean A, Popa D, Mocan T, Cristea V, Neagoe I. Th1 and Th2 profiles in patients
with pancreatic cancer compared with chronic pancreatitis. Pancreas. 2009
Jul;38(5):594-5.Factor de impact 2,733
60. I. Berindan Neagoe, O. Balacescu, C. Burz, C. Braicu, L. Balacescu, O. Tudoran,
T.Kaucsar, V.Cristea, A. Irimie. p53 gene therapy using RNA interference. Journal of
B.U.O.N.14,SEPT 2009, S 51-S 59 Factor de Impact 0.783
27
2010-
61. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, Esteban E,
Molinier O, Brugger W, Melezínek I, Klingelschmitt G, Klughammer B, Giaccone G;
SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-
cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
Lancet Oncol. 2010 Jun;11(6):521-9. Epub 2010 May 20.PMID: 20493771 Factor de
impact 10.119
62. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV,
Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M, Ganea-Motan E,
Ciuleanu T, Wimberger P, Schmittel A, Schmalfeldt B, Burges A, Bokemeyer C,
Lindhofer H, Lahr A, Parsons SL. The trifunctional antibody catumaxomab for the
treatment of malignant ascites due to epithelial cancer: Results of a prospective
randomized phase II/III trial. Int J Cancer. 2010 Apr 27. [Epub ahead of print]PMID:
20473913 Factor de impact 4.693
63. Steger GG, Abrahámová J, Bacanu F, Brincat S, Brize A, Cesas A, Cufer T, Dank M,
Duchnowska R, Eniu A, Jassem J, Kahán Z, Matos E, Padrik P, Plāte S, Pokker H,
Purkalne G, Timcheva C, Tzekova V, Vyzula R, Zielinski CC. Current standards in the
treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central
European Consensus Panel. Wien Klin Wochenschr. 2010 Jun;122(11-12):368-79.
Epub 2010 Jun 15.PMID: 20549373 Factor de impact 0.804
64. Cornelia Braicu, Dumitrita Rugina, Veronica Sanda Chedea, Oana Tudoran, Ovidiu
Balacescu, Ioana Neagoe And Carmen Socaciu, Protective action of different natural
flavan-3-ols against aflatoxin B1-related cytotoxicity, Journal of Food Biochemistry,
Volume 34 Issue 3, Pages 595 – 610, Published Online: 3 Mar 2010; ISI, Factor de
impact (2009)=0.779; nr de citari -1 in sistem Google Scholar.
28
65. Achimaş-Cadariu P, Irimie A, Achimaş-Cadariu L, Neagoe I, Buiga R. Chirurgia (Bucur).
2009 May-Jun;104(3):287-93. ISI
66. Cornelia Braicu, Ioana Berindan-Neagoe, Veronica Sanda Chedea, Loredana
Balacescu, Ioana Brie, Olga Soritau, Carmen Socaciu, Alexandru Irimie. Individual
and combined cytotoxic effects of the major four aflatoxins in different in vitro
stabilized systems, Journal of Food Biochemistry Published Online: Mar 3 2010
4:34AM, DOI: 10.1111/j.1745-4514.2010.00350.x ISI, Factor de impact (2009)=0.77.
67. Veronica Sanda Chedea, Cornelia Braicu, Carmen Socaciu, Antioxidant/prooxidant
activity of a polyphenolic grape seed extract, Food Chemistry , Volume 121, Issue 1,
Published Online: 1 July 2010, Pages 132-139, doi:10.1016/j.foodchem.2009.12.020
ISI Factor de impact (2009)= 3.146
68. Rantakari P, Nikkilä J, Jokela H, Ola R, Pylkäs K Lagerbohm H, Sainio K, Poutanen M,
Winqvist R. Inactivation of Palb2 gene leads to mesoderm differentiation defect and
early embryonic lethality in mice. Hum Mol Genet. 2010 Aug 1;19(15):3021-9. Epub
2010 May 18. ISI, Factor de impact (2010):7.386
69. Jokela H, Rantakari P, Lamminen T, Strauss L, Ola R, Mutka AL, Gylling H, Miettinen T,
Pakarinen P, Sainio K, Poutanen M. Hydroxysteroid (17beta) dehydrogenase 7
activity is essential for fetal de novo cholesterol synthesis and for neuroectodermal
survival and cardiovascular differentiation in early mouse embryos. Endocrinology.
2010 Apr;151(4):1884-92. Epub 2010 Feb 25. ISI, Factor de impact (2009):5.257
70. Jääskeläinen M, Prunskaite-Hyyryläinen R, Naillat F, Parviainen H, Anttonen M,
Heikinheimo M, Liakka A, Ola R, Vainio S, Vaskivuo TE, Tapanainen JS. Mol Cell
29
Endocrinol. 2010 Apr 12;317(1-2):106-11. Epub 2009 Dec 3. WNT4 is expressed in
human fetal and adult ovaries and its signaling contributes to ovarian cell survival.
Mol Cell Endocrinol. 2010 Apr 12;317(1-2):106-11. Epub 2009 Dec 3. ISI, Factor de
impact (2009): 3.503
71. Trifa AP, Cucuianu A, Petrov L, Urian L, Militaru S, Dima D, Pop IV, Popp RA.The G
allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly
associated with JAK2 V617F-positive myeloproliferative neoplasms. Ann. Hematol
2010 Apr 27 (epub ahead of print) – indexat ISI – IF=2.919
72. Trifa AP, Cucuianu A, Popp RA. Development of a reliable PCR-RFLP assay for
investigation of the JAK2 rs10974944 SNP, which might predispose to the
acquisition of somatic mutation JAK2(V617F). Acta Haematol. 2010;123(2):84-7 –
indexat ISI – IF=1.069
73. Cucuianu A, Precup R. A hypothetical-mathematical model of acute myeloid
leukaemia pathogenesis. Computational and Mathematical Methods in Medicine,
2010, 11 (1):49 – 65 – indexat ISI – IF=0
74. I. D. Postescu, P. Virág, M. Achim, E. Fischer-Fodor: Influence of palm oil on
doxorubicine induced cytotoxicity in normal and tumor cell cultures, Phytoter. Res.
2010, 24, 154-156, i.f. 1.772.
75. L. I. Sabău, G. Damian, D. Daicoviciu, A. Mureăan, I. D. Postescu, D. Mihu, C. Mihu,
N. Costin, C. Alb: In vivo study regarding antioxidant effect of red grape polyphenol
extract using biochemical and FT-IR methods, J.Optoel.Adv.Mater. (JOAM), 2(1),
2010, 44-49, i.f. 0.577.
30
76. T. Dicu, I. D. Postescu, C. Tatomir, M. Tămaş, C. Cosma: A method to measure the
antioxidant properties of polyphenolic compounds in trapping DPPH radical, under
review at Ital.J.Food Sci, 2010, i.f. 0.462.
77. I. D. Postescu, P. Virág, T. Dicu, C. Tatomir, E. Fischer-Fodor, I. Brie, M. Perde-
Schrepler, I. V. Cernea: The cyto- and radioprotective effects of a whey protein
isolate, under review at Dairy Sci. Technol, 2010, i.f. 1.012.
78. C. Tomuleasa, O. Soriţãu, I. Brie, E. Páll, V. Foris, T. Dicu, P. Virag, A. Irimie, G.
Kacsó: Mesenchymal stem cell irradiation in culture engages differential effect of
hyperfractionated radiotherapy for head and neck cancers, Journal of Balkanic
Union of Oncology, 15:348-356, 2010.Factor de Impact 0.783
79. C. Tomuleasa, O. Soriţău, D. Rus-Ciucă, T. Pop, D. Todea, O. Mosteanu, B. Pintea, V.
Foris, S. Şuşman, G. Kacsó, A. Irimie: Isolation and Characterization of Hepatic
Cancer Cells with Stem-like Properties from Hepatocellular Carcinoma, J
Gastrointestinal Liver Dis, 19, 1, 2010, 61-67, i.f. 1.265.
80. O. Soritau, C. I. Tomuleasa, E. Pall, P. Virag, E. Fischer-Fodor, V. Foris, O. Barbos, C.
Tatomir, G. Kacso, A. Irimie: Enhanced chemoresistance and tumor sphere formation
as a laboratory model for peritoneal micrometastasis in epithelial ovarian cancer,
Romanian Journal of Morphology and Embryology, 2010, 51 (2): 259-64.
81. C. Tomuleasa, G. Kacso, O. Soritau, S. Susman, A. Irimie, P. Virag: Cellular
interactions in prostate cancer genesis and dissemination. Looking beyond the
obvious, Romanian Journal of Morphology and Embryology, 2010, 51 (3): 3-6.
82. C.G. Precup, D. Gonganau-Nitu, R.R. Scurtu, G. Dindelegan, A. Biro, O. Soritau, C.
Crişan, O. Serban, G. Pufu, C. Ciuce.: Assessement by laser Doppler of the peripheral
31
tumour perfusion after radiofrequency ablation for colorectal liver mestasis-
experimental study. Chirurgia (Bucur). 2010 Jan-Feb;105(1):71-6.
83. O. Lucaciu, M. Băciuţ, G. Băciuţ, R. Câmpian, O. Soriţău, S. Bran, B. Crişan, L.
Crişan.: Tissue engineered bone versus alloplastic commercial biomaterials in
craniofacial reconstruction. Rom J Morphol Embryol. 2010;51(1):129-36.
84. S.Clichici, A.Filip, D. Daicoviciu, R.M. Ion, T. Mocan, C.Tatomir, L.Rogojan,
D.Olteanu, A. Muresan: The dynamics of reactive oxygen speciesin photodynamic
therapywith tetra sulfophenil- porphyrin. Acta Physiologica Hungarica, vol 97 (1), 43-
55, 2010. ISSN 0231-424X (ISI), i.f. 0.491.
32
Citari ISI
1. Erlotinib in previously treated non-small-cell lung cancer
nejm.org [HTML]… Rodrigues Pereira, T Ciuleanu, EH Tan, V … - … England Journal of …,
2005 - content.nejm.org. Results The median age of the 731 patients who underwent
randomization was 61.4 years; 49 percent had received two prior chemotherapy
regimens, and 93 percent had received
platinum-based chemotherapy. The response rate was 8.9 percent in the erlotinib group
...
Citat de 2032 ori - Articole cu conţinut similar - Toate cele 17 versiuni
2. Gefitinib plus best supportive care in previously treated patients with refractory
advanced non-small-cell lung cancer: results from a randomised, placebo-controlled,
…pharmacist.or.kr [PDF]… P Parikh, J Rodrigues Pereira, T Ciuleanu, J von Pawel … - The
Lancet, 2005 - Elsevier
1129 patients were assigned gefitinib and 563 placebo. At median follow-up of 7·2
months, median survival did not differ significantly between the groups in the overall
population (5·6 months for
gefitinib and 5·1 months for placebo; hazard ratio 0·89 [95% CI 0·77–1·02], p=0·087) or
...
Citat de 941 ori - Articole cu conţinut similar - Toate cele 11 versiuni
3. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in
advanced non-small-cell lung cancer\ascopubs.org [HTML]… , JR Pereira, T Ciuleanu, J
von Pawel, C … - Journal of Clinical …, 2006 - jco.ascopubs.org
Results High EGFR gene copy number was a predictor of a gefitinib-related effect on
33
survival
(hazard ratio [HR], 0.61 for high copy number and HR, 1.16 for low copy number;
comparison
of high v low copy number HR, P = .045). EGFR protein expression was also related to ...
Citat de 315 ori - Articole cu conţinut similar - Toate cele 10 versiuni
4. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine
or best supportive care in advanced non-small cell lung cancer: A phase III …… , R
Ramlau, N Ghilezan, T Ciuleanu, B Cucevic, K … - Lung Cancer, 2006 - Elsevier
Between November 1999 and November 2002, we enrolled 352 patients (median age:
57 years; stage IV disease: 74%; Karnofsky performance status (KPS) >80: 41%).
Following initial therapy, 206 patients were randomized and treated with gemcitabine
(138) or best ...
Citat de 72 ori - Articole cu conţinut similar - Toate cele 4 versiuni
5. Phase III trial comparing supportive care alone with supportive care with oral topotecan
in patients with relapsed small-cell lung cancer ascopubs.org [HTML]MER O'Brien, TE
Ciuleanu, H Tsekov, Y … - Journal of Clinical …, 2006 - jco.ascopubs.org
RESULTS: In the intent-to-treat population, survival (primary end point) was prolonged in
the topotecan group (log-rank P = .0104). Median survival with BSC was 13.9 weeks (95%
CI, 11.1 to 18.6) and with topotecan, 25.9 weeks (95% CI,18.3 to 31.6). Statistical
significance for ...
Citat de 84 ori - Articole cu conţinut similar - Toate cele 9 versiuni
6. D Cosaceanu, RA Budiu, M Carapancea, J Castro, R … - Oncogene, 2006 - nature.com
Ionizing radiation exposure results in the activation of several tyrosine kinase receptors
that participate in radiation-induced DNA damage response and radioresistance. We
34
previously showed that insulin-like growth factor 1 receptor (IGF-1R) inhibition
enhanced radiosensitivity of non- ...
Cited by 21 - Related articles - BL Direct - All 5 versions
7. Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving
chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized,
…ascopubs.org [PDF]…
Pinter, M Smakal, TE Ciuleanu, L Chen, T … - Journal of Clinical …, 2008 -
jco.ascopubs.orgRobert E. Smith Jr, Matti S. Aapro, Heinz Ludwig, Tamás Pintér, Martin
Šmakal, Tudor E. Ciuleanu, Li Chen, Tom Lillie, and John A. Glaspy From the South
Carolina Oncology Associates, Columbia, SC; Amgen Inc, Thousand Oaks; University of
California, Los ...
Citat de 68 ori - Articole cu conţinut similar - Toate cele 8 versiuni
8. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive
care for non-small-cell lung cancer: a randomised, double-blind, phase 3
…oncobaleares.es [PDF]
T Ciuleanu, T Brodowicz, C Zielinski, JH Kim, M … - The Lancet, 2009 - ElsevierThis
randomised double-blind study was undertaken in 83 centres in 20 countries. 663
patients with stage IIIB or IV disease who had not progressed on four cycles of platinum-
based chemotherapy
were randomly assigned (2:1 ratio) to receive pemetrexed (500 mg/m 2 , day 1) plus best
...
Citat de 68 ori - Articole cu conţinut similar - Toate cele 14 versiuni
9. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive
care for non-small-cell lung cancer: a randomised, double-blind, phase 3
35
…oncobaleares.es [PDF]T Ciuleanu, T Brodowicz, C Zielinski, JH Kim, M … - The Lancet,
2009 - Elsevier
This randomised double-blind study was undertaken in 83 centres in 20 countries. 663
patients
with stage IIIB or IV disease who had not progressed on four cycles of platinum-based
chemotherapy
were randomly assigned (2:1 ratio) to receive pemetrexed (500 mg/m 2 , day 1) plus best
...
Cited by 62 - Related articles - All 14 versions
10. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with
limited-stage small-cell lung cancer in complete remission after … maastro.nl [PDF]… ,
E Quoix, C Faivre-Finn, T Ciuleanu, R Arriagada, R … - Lancet Oncol, 2009 -
maastro.nlStandard-dose versus higher-dose prophylactic cranial ... RTOG 0212, and IFCT
99-01): a randomised
clinical trial ... Cécile Le Péchoux, Ariane Dunant, Suresh Senan, Aaron Wolfson, Elisabeth
Quoix, Corinne Faivre-Finn, Tudor Ciuleanu, Rodrigo Arriagada, Richard Jones, Rinus ...
Citat de 12 ori - Articole cu conţinut similar - Afişare ca HTML - Toate cele 13 versiuni
12. SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus
placebo following nonprogression with first-line platinum-based chemotherapy …
F Cappuzzo, T Ciuleanu, L Stelmakh, S … - ASCO Meeting …, 2009 - meeting.ascopubs.org
Background: Erlotinib (E), a small-molecule EGFR TKI, is proven to extend survival versus
placebo
(P) in 2nd/3rd-line advanced NSCLC. The phase III SATURN study (BO18192) was initiated
to evaluate E as maintenance therapy after standard 1st-line platinum-based ...
Cited by 53 - Related articles
11. A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or
platinum-refractory ovarian cancer AM Vlad, RA Budiu, DE Lenzner, Y Wang, JA … -
36
Cancer Immunology, …, 2010 - SpringerCancer Immunol Immunother (2010) 59:293–301
DOI 10.1007/s00262-009-0750-3 ... A phase
II trial of intraperitoneal interleukin-2 in patients ... Anda M. Vlad · Raluca A. Budiu ·
Diana E. Lenzner · Yun Wang · Julia A. Thaller · Kelly Colonello · Peggy A. Crowley-Nowick
· ...
Cited by 1 - Related articles - All 4 versions
12. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with
carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 … M
Smakal, TE Ciuleanu, SV Orlov, M … - Journal of Thoracic …, 2008 -
journals.lww.comCorey J. Langer, MD, FACP,* Kenneth J. O'Byrne, MD,† Mark A.
Socinski, MD,‡ Sergei M.
Mikhailov, MD,§ Krzysztof Lesniewski-Kmak, MD, Martin Smakal, MD,¶ Tudor E.
Ciuleanu, MD,#
Sergey V. Orlov, MD,** Mircea Dediu, MD, PhD,# David Heigener, MD,†† Amy J.
Eisenfeld ...
Cited by 21 - Related articles - BL Direct - All 5 versions
13. [CITATION] Results from a phase III, randomized, double-blind, placebo-controlled study
of darbepoetin alfa for the treatment of anemia in patients not receiving M Aapro, H
Ludwig, T Pinter, M Smakal, T Ciuleanu, L … - CA: American Association …, 2007
Cited by 19 - Related articles
14. [CITATION] Molecular analysis of EGFR gene copy number, EGFR expression, and Akt
activation status in advanced non-small cell lung cancer (aNSCLC) treated A Chang, P
Parikh, JR Pereira, T Ciuleanu, J Pawel, B … - Clin Cancer Res, 2005
Cited by 19 - Related articles
15. [CITATION] Survival benefit of oral topotecan plus supportive care versus supportive
care alone in relapsed, resistant SCLC MO'Brien, T Ciuleanu, H Tsekov, Y Shparyk, B
37
Čučević, … - Lung Cancer, 2005
Cited by 17 - Related articles
16. Phase II open label randomized study of trabectedin (T) given as two different dosing
schedules in women with platinum-sensitive, recurrent ovarian carcinoma: A Roszak, T
Ciuleanu, M Bidzinski, T … - ASCO Meeting …, 2006 - meeting.ascopubs.org
schedules in women with platinum-sensitive, recurrent ovarian carcinoma: Preliminary
results. J. Del Campo, A. Roszak, T. Ciuleanu, M. Bidzinski, T. Hogberg, M. Wojtukienicz,
K. Boman, A. Poveda, A. Westermann and M. Izquierdo ...
Cited by 15 - Related articles - All 2 versions
17. [CITATION] A randomized placebo-controlled trial of erlotinib in patients with advanced
non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line FA Shepherd, J
Pereira, TE Ciuleanu, S Hirsh - J Clin Oncol, 2004
Cited by 14 - Related articles
18. PDF] Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients
with limited-stage small-cell lung cancer in complete remission after …
maastro.nl [PDF]… , E Quoix, C Faivre-Finn, T Ciuleanu, R Arriagada, R … - Lancet Oncol,
2009 - maastro.nl
Standard-dose versus higher-dose prophylactic cranial ... RTOG 0212, and IFCT 99-01): a
randomised clinical trial ... Cécile Le Péchoux, Ariane Dunant, Suresh Senan, Aaron
Wolfson, Elisabeth
Quoix, Corinne Faivre-Finn, Tudor Ciuleanu, Rodrigo Arriagada, Richard Jones, Rinus ...
Cited by 12 - Related articles - View as HTML - All 13 versions
19. [PDF] Efficacy and safety of AZD6244 (ARRY-142886) as second-or third-line treatment of
patients with advanced non-small cell lung cancer arraybiopharma.com [PDF]… , C
Cebotaru, T Ciuleanu, D Damjanov, H … - ASCO Annual …, 2008 - arraybiopharma.com
EFFICACY AND SAFETY OF AZD6244 (ARRY-142886) AS SECOND- OR THIRD-LINE
TREATMENT
OF ... PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER ... V. Tzekova1, C.
38
Cebotaru2, T. Ciuleanu2, D. Damjanov3, H. Ganchev4, V. Kanarev5, P. Stella6, N. Cited by
10 - Related articles - View as HTML - All 5 versions
20. Phase III study of pemetrexed plus carboplatin compared with etoposide plus
carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer
ascopubs.org [HTML]… , NA Karaseva, T Ciuleanu, J Jassem, M … - Journal of Clinical …,
2009 - jco.ascopubs.org
From the Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel
Hill, NC; Vrije University Medical Center, Amsterdam; Eli Lilly Netherlands, Utrecht, the
Netherlands; Christie Hospital, Manchester, United Kingdom; US Oncology, Houston, TX;
...
Cited by 11 - Related articles - All 7 versions
21. Phase II randomized study of trabectedin given as two different every 3 weeks dose
schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum- M
Bidzinski, TE Ciuleanu, T Hogberg, MZ … - Annals of …, 2009 - Eur Soc Med Oncology
Results: ORR was 38.9% [95% confidence interval (CI) 25.9% to 53.1%; arm A] and 35.8%
(95% CI 23.1% to 50.2%; arm B) (intention-to-treat primary analysis). Median time to
progression was 6.2 months (95% CI 5.3–8.6 months; arm A) and 6.8 months (95% CI
4.6–7.4 months; ...
Cited by 9 - Related articles - All 6 versions
22. A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as
first-line treatment in patients with advanced biliary cancersT Ciuleanu, M Diculescu,
NM Hoepffner, J Trojan … - Investigational new …, 2007 - Springer
Summary The prognosis of advanced biliary tract carcino- ma is poor with chemotherapy
limited to a palliative role. This randomised study was designed to evaluate the
effectiveness of a new liposomal thymidylate synthase inhibitor (TSI), OSI-7904L, in
parallel with a modified de ...
Cited by 9 - Related articles - BL Direct - All 5 versions
23. [CITATION] Darbepoetin alfa (da) 500mcg or 300mcg once every three weeks (q3w) with
or without iron in patients (pts) with chemotherapy-induced anemia (CIA) T Silberstein, T
39
Webb, S Averyanova, T Ciuleanu, L … - Ann Oncol, 2008
Cited by 7 - Related articles
24. [CITATION] National Cancer Institute of Canada Clinical Trials Group Shepherd, J
Rodrigues Pereira, T Ciuleanu, EH Tan, V … - … -cell lung cancer. N Engl J …, 2005
Cited by 7 - Related articles
25. [CITATION] Central European Cooperative Oncology Group CECOG. Cisplatin and
gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best …R
Ramlau, N Ghilezan, T Ciuleanu, B Cucevic, K … - Lung Cancer, 2006
Cited by 7 - Related articles
26. [CITATION] on behalf of the SATURN Investigators. SATURN: A double-blind,
randomized, phase III study of maintenance erlotinib versus placebo following …
27. F Cappuzzo, T Ciuleanu, L Stelmakh, S Cicenas, A … - J Clin Oncol, 2009
Cited by 7 - Related articles
28. [CITATION] SATURN: a double blind, randomized, phase III study of maintenance
erlotinib versus placebo following nonprogression with first-line platinum-based
29. F Cappuzzo, T Ciuleanu, L Stelmakh… - Proc Am Soc Clin Oncol, 2009
Cited by 7 - Related articles
30. I.D. Postescu, C. Tatomir, G. Cherecheş, I. Brie, G. Damian, D. Petrişor, A-M Hosu, V.
Miclăuş, A. Pop: Spectroscopic characterization of some grape extracts with potential
role in tumor growth inhibition, Journal of Optoelectronics and Advanced Materials,
2007, 9(3), 564-567, i.f. 0.577.
1 citare:Top of Form
Bottom of Form
31. Multi-experimental Characterization of Grape Skin Extractsagriculturejournals.cz [PDF]L
ŠŤAVÍKOVÁ, M POLOVKA, B HOHNOVÁ, J … - agriculturejournals.cz antioxidants: Spin
trapping EPR and optical study. Free Radical Biology and Medicine, 31:43–52. Postescu
ID, Tatomir C., Chereches G., Brie I.. Damian G., Petrisor D., Hosu A.-M., Miclaus V., Pop
A. (2007):
40
32. Spectroscopic characterization of some grape extracts with ... Articole cu conţinut
similar - Afişare ca HTML - Toate cele 7 versiuni
A.Dorhoi, V. Dobrean, M. Zahan, P. Virág. Modulatory effects of several herbal extracts
on avian peripheral blood cell immune responses, Phytother. Res., Vol. 20, 2006, 352-
358, i.f. 1.772.
14citari:http://scholar.google.ro/scholar?cites=15103764961601747767&as_sdt=2005&
sciodt=2000&hl=ro
32. A.Filip, S. Clichici, A. Mureşan, D. Daicoviciu, C. Tatomir, C. Login, S. Dreve, C.
Gherman: Effects of PDT with 5-aminolevulinic acid and chitosan on Walker
Carcinosarcoma. Exp. Oncol., 2008, 30, 3, 212-219, i.f. 0.115.
4citari:http://scholar.google.ro/scholar?cites=14195523122993684921&as_sdt=2005&s
ciodt=2000&hl=ro
33. P.Virág, I. Brie, I.D. Postescu, M. Perde-Schrepler, E. Fischer-Fodor, O. Soriţău, A.
Irimie, V. Cernea. Comparative study of two evaluation methods for the genotoxic
effects of environmental heavy metals on normal cells, Toxicol. Ind. Health, 25 (4-5),
2009, 253-8, i.f. 0.700.
2citari:http://scholar.google.ro/scholar?cites=3589248269522944064&as_sdt=2005&sci
odt=2000&hl=ro
34. Cucuianu A, Patiu M, Rusu A. Hepcidin and multiple myeloma related anemia.
Medical Hypotheses, ISSN 0306-9877, 66:352-354, 2006 – 1 citare: Katodritou E, Terpos E,
Zervas A. et al. Hypochromic erythrocytes (%): a reliable marker for recognizing iron-
restricted erythropoiesis and predicting response to erythropoietin in anemic patients
with myeloma and lymphoma. Ann. Hematol, 2007, 86:352-354
35.WNT4 is expressed in human fetal and adult ovaries and its signaling contributes to
ovarian cell survival
M Jääskeläinen, R Prunskaite-Hyyryläinen, F … - Molecular and cellular …, 2009 –
Elsevier Minna Jääskeläinen a , b , Renata Prunskaite-Hyyryläinen c , d , Florence Naillat
41
c , d , HelkaParviainen f , g , h ... in the regulation of apoptosis in mammalian ovaries
([Inoue et al., 2003] and[Jaaskelainen et al ... HCl in a microwave oven (700 W for 2 min
and 300 W for 15 min) was ...
Cited by 1 - Related articles - All 3 versions
36.Ronco G, van Ballegooijen M, Becker N, Chil A, Fender M, Giubilato P, Kurtinaitis J,
Lancucki L, Lynge E, Morais A, O’Reilly M, Sparen P, Suteu O, Rebolj M, Veerus P, Primic
Zakelj M, Anttila A. Process performance of cervical screening programmes in Europe.
Eur J Cancer 2009;45(15):2629-2722.
Citări în reviste indexate ISI:
a. Ronco G, Anttila A. Cervical cancer screening in Europe – changes over the last 9 years.
Eur J Cancer 2009;45(15):2629-2631.
b. Anttila A, von Karsa L, Aasmaa A, Fender M, Patnick J, Rebolj M, Nicula F, Vass L,
Valerianova Z, Voti L, Sauvaget C, Ronco G. Cervical cancer screening policies and
coverage in Europe. Eur J Cancer 2009;45(15):2649-2658.
c. De Vuyst H, Clifford G, Li N, Franceschi S. HPV infection in Europe. Eur J Cancer
2009;45(15):2632-2639.
d. Anttila A, Ronco G. Working Group on the Registration and Monitoring of Cervical Cancer
Screening Programmes in the European Union; within the European Network for
Information on Cancer (EUNICE). Description of the national situation of cervical cancer
screening in the member states of the European Union. Eur J Cancer 2009;45(15):2685-
2708.
e. Low Proportion of False-Negative Smears in the Finnish Program for Cervical Cancer
Screening. Stefan Lönnberg1,2, Ahti Anttila1, Laura Kotaniemi-Talonen1, Harry Kujari4,
Jukka Melkko5, Gustav Granroth6, Martine Vornanen7, Timo Pietiläinen8, Anna Sankila3,
Johanna Arola3, Tapio Luostarinen1 and Pekka Nieminen. Cancer Epidemiology
Biomarkers 2009, &Prevention, 2010,;19:381
42
f. Austin M. Onosko A. Druzdzel M. The Pittsburg Cervical Cancer Screening Model. Arch
Pathol Lab Med 2010;134:744-750.
g. PE Castle a , J Bulten b , M Confortini c , P Klinkhamer d , A Pellegrini e , AG Siebers b G
Ronco f , M Arbyn . Age-specific patterns of unsatisfactory results for conventional Pap
smears and liquid-based cytology: data from two randomised clinical trials. BJOG 2010,
VOL 117(9):1067-1073.
37. Anttila A, Ronco G. Working Group on the Registration and Monitoring of Cervical Cancer
Screening Programmes in the European Union; within the European Network for
Information on Cancer (EUNICE). Description of the national situation of cervical cancer
screening in the member states of the European Union. Nicula F, Suteu O, Pais R, Neamtiu
L.Cervical cancer screening in Romania. Eur J Cancer 2009;45(15):2685-2708.
3 citari
Citări în reviste indexate ISI:
a. Arbyn M, Rebolj M, De Kok I.M.C.M., Fender M, Becker N, O’Reilly M, Andrae B. The
challenges of organising cervical screening programmes in the 15 old member states of
the European Union. Eur J Cancer 2009;45 (15):2671-2678.
b. Nicula F. Al, Anttila A, Neamtiu L, Primic Žakelj M, Tachezy R, Chil A, Grce M, Kesić V.
Challenges in starting organised screening programmes for cervical cancer in the new
member states of the European Union. Eur J Cancer 2009; 45(15):2679-2684.
c. Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975
1. C. La Vecchia1,2,
2. C. Bosetti1,*,
3. F. Lucchini3,
4. P. Bertuccio1,
5. E. Negri1,
6. P. Boyle4 and
7. F. Levi3
43
38.Apoptosis in cancer: Key molecular signaling pathways and therapy targets
C Burz, I Berindan-Neagoe, O Balacescu, … - Acta …, 2009 - informahealthcare.com
Apoptosis is a physiological process vital for embryologic development and the maintenance
of homeostasis in multicellular organisms, but it is also involved in a wide range of pathological
processes, including cancer. In mammalian cells, apoptosis has been divided into two ...
Cited by 8 - Related articles - All 5 versions
39. C BRAICU, I BERINDAN-NEAGOE, VS … - Journal of Food … - interscience.wiley.com
CORNELIA BRAICU1,4, IOANA BERINDAN-NEAGOE1,2, VERONICA SANDA CHEDEA3, LOREDANA
BALACESCU1, IOANA BRIE1, OLGA SORITAU1, CARMEN SOCACIU3 and
ALEXANDRU IRIMIE1,2 1Cancer Institute “I Chiricuta” 34-36 Republicii st. 400015 Cited by 1 -
Related articles
40. [PDF] In vitro evaluation of the chemoprotective action of flavan-3-ols against
deoxynivalenol related toxicityibna.ro [PDF]C Braicu, I Berindan-Neagoe, O Tudoran, O … -
Archiva Zootechnica, 2009 - ibna.ro
In vitro evaluation of the chemoprotective action of ...
Cornelia Braicu 1† , Ioana Berindan-Neagoe 1,2 , Oana Tudoran 1 , ... O. Balacescu 1 , Dumitrita
Rugina 3 , Claudia Gherman 1 , ... 1 Cancer
Institute “I Chiricuta”, Cluj-Napoca, Romania 2 University of Medicine and Pharmacy “Iuliu ...
Cited by 1 - Related articles - View as HTML
41. Protective action of different natural flavan-3-ols against aflatoxin B1-related cytotoxicity, O
TUDORAN, O BALACESCU, I NEAGOE … - Journal of Food … - interscience.wiley.comVet.
Immunol. Immunopathol. 18, 199–209. BRAICU, C., BERINDAN-NEAGOE, I., BURZ, C.,
BALACESCU, O. and IRIMIE, A. 2009a. ... BRAICU, C., BERINDAN-NEAGOE, I., TUDORAN,
O.,BALACESCU, O., RUGINA, D., GHERMAN, C., SOCACIU, C. and IRIMIE, A. 2009b. ...
Cited by 1 - Related articles - All 2 versions
42. p53 gene therapy using RNA interference.
44
I Berindan-Neagoe, O Balacescu, C Burz, … - Journal of BU ON.: …, 2009 - ncbi.nlm.nih.gov1. J
BUON. 2009 Sep;14 Suppl 1:S51-9. p53 gene therapy using RNA interference.Berindan-Neagoe
I, Balacescu O, Burz C, Braicu C, Balacescu L, Tudoran O, Cristea V, IrimieA. Cancer Institute
I.Chiricuta, Cluj Napoca, Romania. [email protected]. Cited by 1
43. Gene expression profiling of primary cutaneous melanoma and clinical outcome
oxfordjournals.org [HTML]… Ortiz Romero, T Robert, O Balacescu, … - JNCI Journal of the …,
2006 - jnci.oxfordjournals.org
Background: Gene expression profiling data for human primary cutaneous melanomas are
scarce because of the lack of retrospective collections of frozen tumors. To identify differentially
expressed genes that may be involved in melanoma progression and prognosis, we investigated
the ...
Cited by 107 - Related articles - BL Direct - All 10 versions
Reprezentant legal
Institutul Oncologic “Prof Dr I.Chiricuta”
Manager
Conf.Dr.Alexandru Irimie
Director cercetare - dezvoltare
Sef lucrari . Dr. Ioana Neagoe
45
ANEXA 4.3 Produse si tehnologii rezultate din activitati de cercetare, bazate pe
brevete, omologari sau inovatii proprii. Studii prospective si tehnologice si
servicii rezultate din activitatea de cercetare-dezvoltare, comandate de
beneficiar
85. 11 x 20 = 220
86. Nicolae Todor Soft pentru evaluarea lezării nucleului prin testul cometei - 2005 –
utilizat în mod curent în cadrul IOCN
87. Nicolae Todor Baza de date pentru calculul timpilor de iradiere si managementul
unei sectii de radioterapie externa -2007 – utilizat în mod curent în cadrul IOCN
88. Nicolae Todor Baza de date pentru elaborarea rezultatelor si managementul unui
platou de imagistica - 2007 – utilizat în mod curent în cadrul IOCN
89. Nicolae Todor Baza de date privind administrarea schemelor de citostatice – 2006 –
utilizat în mod curent în cadrul IOCN
90. Nicolae Todor Baza de date pentru elaborarea rezultatelor si managementul sectiei
de anatomie patologica -2006 – utilizat în mod curent în cadrul IOCN
91. Tehnologia microarray Agilent WHG (2007-prezent) – identificare de noi molecule
in diagnostic molecular- Proiecte de cercetare ; utilizator IOCN proiecte cod: PNII
Breastomics nr contract 42029/2007 ; IDEI ID cod 314/2007 ; Cervixarray 42-
160/2008 ;
92. Tehnologia PCR array (2007-prezent)- identifucare de mecanisme moleculare
deficitare in patologia maligna; utilizator IOCN proiect: de cercetare IDEI ID cod
314/2007
93. Luciana Neamtiu Baza de date pentru elaborarea rezultatelor si managementul
laboratorului de citologie -2008 – utilizat în mod curent în cadrul IOCN
94. Luciana Neamtiu Baza de date si sistem de management pentru programele de
screening populational pentru cancerul de col uterin – 2005
95. Luciana Neamtiu – Sistem informatic pentru managementul Registrul regional de
cancer Nord-Vest – utilizat în mod curent în IOCN
46
Reprezentant legal
Institutul Oncologic “Prof Dr I.Chiricuta”
Manager
Conf.Dr.Alexandru Irimie
Director cercetare - dezvoltare
Sef lucrari . Dr. Ioana Neagoe
Anexa 5.1. Lucrări ştiinţifice (tehnice) publicate in reviste de specialitate8)
47
41 X 5 PUNCTE =205
2005
1. O. Balacescu, Ioana Neagoe, Roxana Ola, L. Vlase, Marcela Achim, S.E. Leucuta.
Farmacocinetica Doxorubicinei in organe dupa administrare la soareci sub forma libera
si incapsulata in lipozomi. Clujul Medical vol. LXXVIII no.1-2005 – 192-199.
2. O. Balacescu, L. Vlase, Marcela Achim, Ioana Neagoe, Roxana Ola, , S.E. Leucuta. Studii
preclinice de Farmacocinetică asupra Doxorubicinei libere şi încapsulate în lipozomi
(Caelyx). Clujul Medical vol. LXXVIII no.1-2005 – 199-205.
3. Ioana Berindan-Neagoe, O. Balacescu, Rodica Risca, Victor Cristea. Molecule de
adeziune celulara in invazie si metastazare. Evidentierea moleculei E-caderina, produs
al genei CDH1- gena supresoare tumorala. Clujul Medical vol. LXXVIII no.2-2005 pp.
409-415.
4. Daniela Todea, Marina Barsu, Silvia Coroianu, G. Muresan, Luminita Lelutiu, R. Buiga,
G. Laszlo , Angiogeneza in carcinomul in situ, microinvaziv si invaziv al colului uterin –.
Clujul Medical 2: 358-364, 2005.
5. Claudia Ordeanu, V.Cernea, N.Ghilezan: Clinical application of the variation of
dose/fraction used in the brachitherapy of cervical cancer”, articol, Clujul Medical, vol.
LXXVIII, 2005: 343-351
6. Doina Piciu, A Irimie, A.Bara, C.Cebotaru – Radionuclide Treatment of Metastatic Bone
Pain Experience of the I. Oncologic Cluj Napoca; Clujul Medical LXXVIIInr.12005 73-79
7. O. Coza, O. Soriţău, I. Brie, V. Cernea: Predictive assays in radiotherapy: cellular
clonogenic survival (colony assay). Methodology of in vitro measurement, Clujul
Medical, 2005.
2006
48
8. Luciana Neamţiu, A Markov Model in Cervical Cancer Screening Strategy,
Creative Mathematics and Informatics, North University of Baia Mare, Department of
Mathematics and Computer Science, Vol. 16, 2006, ISSN 1584-286X, p. 91-94.
9. Doina Piciu, Cosmin Lisencu, Adela Bara, Florin Stamatian, Carmen Georgescu-
Diagnosis and Treatment of Thyroid Carcinoma in Pregnancy – Case Report –
Romanian Journal of Endocrinology and Metabolism, vol 5 nr 4; 2006 p 25-33
10. Suteu O., Nicula F., Irimie A., Lazar L., Pais R., Duma M., Neamtiu L., Coza D., Farcas
M., “Strategies of cervical cancer prevention in Cluj County, Romania”, Abstracts
Volume pg 440, 6th International Multidisciplinary Congress EUROGIN 2006, Paris, 04 /
2006
11. A. Mureşan, Ş. Suciu, S. Clichici, I. D. Postescu, D. Daicoviciu, N. Pop: Study on the
effect of a grape seed extract in Ehrilch carcinoma, Buletinul Universităţii de Ştiinte
Agricole si Medicină Veterinară, 2006, 63, 114-119.
12. Cucuianu A, Stoia M, Farcas A, Dima D, Zdrenghea M, Patiu M, Olinic D, Petrov L.
Arterial Stenosis and Atherothrombotic Events in Polycythemia Vera and Essential
Thrombocythemia. Rom J Intern Med, ISSN 1582-3296, 44, 4, 397-406, 2006
2007
13. Teodora Sanislav, Ioan Stoian, Dorina Căpăţînă, Mihaela L. Drăgan, Luciana Neamţiu,
Florian Nicula, Ofelia Şuteu, Liana Lupşa, Data Management System for Cervical Cancer
Screening – CanScreen, Acta Electrotehnica, pp. 43-46, ISSN 1841-3323, Volume 48,
Number 4, septembrie 2007, Cluj-Napoca
14. V.Nagy, N.Todor, O.Coza, C.Ordeanu, N.Ghilezan: Quality of life and treatment related
toxicity in 335 patients with locally advancved cervical carcinoma treated by two
chemoradiation regimens; Journal of BUON 12:389-394,
15. C.Ordeanu, O.Coza, S.Gavriş, N.Todor, E.Szilagy, M.Bako, V.Cernea, N.Ghilezan,
V.Nagy: Clinical results of medium dose rate brachitherapy combined with external
beam radiotherapy in the treatment of advanced cervical carcinome; Journal of BUON
12:221-226, 2007
49
16. TE.Ciuleanu, G.Fountzilas, E.Ciuleanu, M.Palataniotis, N.Todor, N.Ghilezan: Paclitaxel
and carboplatin in relapsed or metastatic nasopharyngeal carcinoma: a multyicenter
phase II study; Journal of BUON 9:161-166, 2007
17. P.Rusu, TE.Ciuleanu, D.Cernea, D.Pelau, V.Gaal, C.Cebotaru, T.Gutman, N.Todor,
N.Ghilezan: Concurrent chemoradiotherapy with vinorelbine and platinum compound
followed by consolidation chemotherapy for unresectable stage III non-small cell lung
cancer: Preliminary results of a phase II study; Journal of BUON 12:33-40, 2007
18. Arbyn M, Primic-Zakelj M, Raifu A.O, Grce M., Paraskevaidis E., Diakomanolis E., Kesic
V., Nicula F.A., Şuteu O., Karsa L. The burden of cervical cancer in South-East Europe at
the beginning of the 21st century. Collegium Antropologicum, 2007; 31(2):7-10.
19. Sanislav T., Stoian I., Căpăţână D., Drăgan M., Neamţiu L., Nicula F., Şuteu O., Lupşa L.,
Data Management System for Cervical Cancer Screening – CanScreen, Acta Electronica
2007;48(4):43-46.
20. Eniu A. Integrating biological agents into systemic therapy of breast cancer:
trastuzumab, lapatinib, bevacizumab. J BUON. 2007 Sep;12 Suppl 1:S119-26.
Review.PMID: 17935269
21. Mihaela HEDEŞIU, Luminita LELUŢIU, Sorana D. BOLBOACĂ, V. POPIŢA, T. Guttman,
Mihaela BACIUŢ, Expression of CD44S Cell Adhesion Molecule in Maxillofacial
Squamous Cell Carcinomas and its Imaging Significance, Revista medico-chirurgicala a
Societatii de Medici si Naturalisti din Iasi, Society of Physicians and Natturalist,
Romania, 112(1), 312-319, 2008, [indexată Medline (PubMed, Index Medicus)],ISSN:
0300-8738,
22. A. Horak, R. Buiga, O. Soriţău, S. Neamţu, M. Cucuianu: Acute Megakaryiocytic and
Myelofibrosis. Considerations based on a case report, Clujul Medical, 2007,1,133-7.
23. O. Soriţău, I. Brie, V. Foris, V. Lung-Illes, V. Cernea: Experimental Model for In vitro
Study and Quantification of Neoangiogenesis, Fiziologia – Physiology, 2007, Suppl. 17,
9-10.
24. O. Lucaciu, D. Ciupercescu, G. Băciuţ, O. Soriţău, I. Groza, M. Băciuţ, E. Páll, S. Bran,
H. Rotaru, C. Dinu, C. Balog, B. Crişan, A. Sava, H. Almăşan: Implicarea celulelor stem
50
în regenerarea tisulară şi în procesele de vindecare. Metode de obţinere de celule stem
embrionare, Revista medico-chirurgicală a Societăţii de Medici şi Naturalişti din Iaşi,1,
2007, 3, supl. 1, 967-972, ISSN 00487848.
25. Cucuianu A. Targeting epigenetics and other pathways in the treatment of
myelodysplastic syndromes. Haema, ISSN 1108-2682, 10, Suppl 2, 56-61, 2007
2008
26. Lupşa R., Lupşa L., Neamţiu L., An Optimal Model to Solve the Transport Problem for
Mammography Screening, lucrare publicată în extenso în Proceedings of 2008 IEEE
Internatinal Conference on Automation, Quality and Testing, Robotics (AQTR 2008), p.
139-142, ISBN 978-1-4244-2576-1.
27. Chiorean I., Lupşa L., Neamţiu L., Markov Models for the Simulation of Cancer
Screening Process, lucrare publicată în Numerical Analysis and Applied Mathematics,
International Conference, pag. 143 – 146.
1. I. D. Postescu, M. Achim, P. Virág, C. Tatomir, M. Perde-Schrepler, D. Colcear, I. V.
Cernea. Efectele citoprotectoare, in vitro, ale unui ulei de palmier cu conţinut în
tocotrienoli, Clujul Medical, Vol. 531, 2008: 126-132.
2. E. Páll, I. Groza, C. Tomuleasa, C. Ober, D. Groza: Isolation and cultivation of mouse
mesenchymal stem cells on polypropylenic scaffold, Bulletin of Agricultural Sciences and
Veterinary Medicine, 2008; 65:139-143.
3. E. Páll, I. Groza, O. Soriţău, L. Cătană, M. Cenariu: Modulation of cardiac differentiation
of mouse embryonic stem cells under the influence of some growth factors, Lucrari
ştiinţifice Medicina Veterinară, Ed. Ioan Ionescu de la Brad Iaşi, ISSN 1454-7406, vol.51
(10), 2008,117-122.
4. E. Páll, I. Groza, O. Soriţău, S. Ciupe, L. Cătană: Isolation, culture and identification of
bone cells from newborne rats, Bulletin of University of Agricultural Sciences and
51
Veterinary Medicine Cluj-Napoca, Veterinary Medicine, pISSN-1843-5270, eISSN 1843-
5378, 2008, 65 (1).
28. E. Páll, I. Groza, C. Tomuleasa, C. Ober, D. Groza: Isolation and cultivation of mouse
mesenchymal stem cells on polypropilenic scaffold, Bulletin of University of Agricultural
Sciences and Veterinary Medicine Cluj-Napoca, Veterinary Medicine, pISSN-1843-5270,
eISSN 1843-5378, 2008, 65 (1).
29. Dima D, Cucuianu A, Petrov L. Cytogenetic and molecular response after Dasatinib in
blastic phase chronic myeloid leukemia. Journal of radiotherapy and medical oncology
2008; 14 (2): 126-128- indexat ISI
2009
30. O. Balacescu, I. Neagoe, L. Balacescu, N. Crisan, B. Feciche, O. Tudoran, I. Coman, A.
Irimie. Angiogenesis serum protein quantification for prostate pathology. Current
Urology, 2008; 2: 181-187.
31. Cornelia Braicu, Claudia Burz, Ioana Berindan-Neagoe, Ovidiu Balacescu, Marcel
Tantau, Victor Cristea, Alexandru Irimie. Molecular markers in the pathogenesis of
cholangiocarcinoma: potential for early detection and selection of appropriate
treatment, Vol. 2, No. 3, 2009.
32. Cornelia Braicu, Claudia Burz, Ioana Neagoe, Ovidiu Balacescu, Florin Graur, Victor
Cristea, Alexandru Irimie, Hepatocellular carcinoma: tumorigenesis and prediction
markers, doi:10.4021/gr2009.07.1304, Publish ahead of print July 23, 2009.
33. Cornelia Braicu, Ioana Berindan-Neagoe, Oana Tudoran, O. Balacescu, Dumitrita
Rugina, Claudia Gherman, Carmen Socaciu, Al. Irimie, In vitro evaluation of the
chemoprotective action of flavan-3-ols against deoxynivalenol related toxicity, 2009,
12(32), 45-55
52
34. Rugina D., Pintea A., Braicu C., Farcal L., Andrei S., Socaciu C., 2009, Rosmarinic acid
reduces oxidation of human retinal epithelial cells, Lucrari Stiintifice USAMV Iasi,
52(11), 250-254, ISSN 1454-7406 (B+ CAB).
35. Cornelia Braicu, Ioana Berindan-Neagoe, Claudia Burz, Ovidiu Balacescu, Alexandru
Irimie, Catechins therapeutic implications in cancer, Biology and Theraphy of Cancer
Cell, 1(1), 2009, 81-84
36. C. I. Tomuleasa, O. Soriţău, V. Foris, E. Pall, V. Lung: The influence of different growth
factors on stem cells in culture, Revista de Medicină şi Farmacie, 2009; 55:37-38.
37. Cucuianu A, Dohner K, Dima D, Schlenk R, Schmidt M, Patiu M, Basarab C, Selicean C,
Bojan A, Vasilache A, Urian L, Torok T, Zdrenghea M, Dohner H, Petrov L. The role of
cytogenetics and molecular genetics in the management of acute myeloid leukemia.
Biology and Therapy of Cancer Cell, 1,1, 51-56, 2009
38. Todor N., Cernea I.V., Chis A.: From Passive to Active in the Design of External
Radiotherapy Database at Oncology Institute "Prof. Dr. Ion Chiricuţă" from Cluj-
Napoca, Applied Medical Informatics, 25 (2009), 7-15
39. Todor N., Brie Ioana, Nagy Viorica, Rusu M., Saplacan G.: A mathematical model of
comets in single cell gel electrophoresis technic for evaluation of DNA damage, Annals
of the Tiberiu Popoviciu Seminar of Functional Equations, Approximations and
Convexity, 7 (2009) 219-228
Reprezentant legal
Institutul Oncologic “Prof Dr I.Chiricuta”
Manager
Conf.Dr.Alexandru Irimie
Director cercetare - dezvoltare
Sef lucrari . Dr. Ioana Neagoe
53
Anexa 5.2.Lucrări ştiinţifice prezentate la conferinţe internaţionale cu comitet de program
159 x 5 = 795
2005
1. Luciana Neamţiu, Databases Applied in Pharmacoeconomic Evaluation, The
Proceedings of the International Conference “The Impact of European Integration on
the National Economy”, Editura Risoprint, 2005, ISBN 973-651-007-0, p.402-406.
2. O. Balacescu, A Kauffmann, I. Neagoe, V Cristea, V. Lazar, G. Vassal. Cisplatin
resistance in ovarian cancer using gene expression microarrays. 17th pezcoller
Symposium. Molecular Understanding of solid tumors. June 16-18, 2005 –Trento,
Italy. in The Pezcoller Foundation Journal, year 13 n.24, pag 24.
3. Ioana Berindan Neagoe, O. Balacescu, Roxana Ola, Al Irimie. APC methylation in
colorectal cancer. 17th pezcoller Symposium. Molecular Understanding of solid
tumors. June 16-18, 2005 –Trento, Italy, in The Pezcoller Foundation Journal, year 13
n.24, pag 27.
4. Ioana Brie, V. Cernea, N.Todor, Maria Perde, Piroska Virag, Eva Fischer, Olga
Soritau, I.D. Postescu, Iolanda Sicoe, Viorica Nagy, N. Ghilezan Prediction by comet
assay of the response to radiotherapy: preliminary results in cervical tumors- The
34th Annual Meeting of the European Society for Radiation Biology (ESRB) and The
Annual Scientific Meeting of the Association for Radiation Research (ARR), Leicester,
Marea Britanie, 5-8 septembrie 2005
5. Chaitchik, O.Soritau, E.Fischer, D.Pelau, L.Lazar, YS Schiffenbauer CellScan
technology for in vitro prediction of tumor response to chemotherapeutic agents,
Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings, 23 (165,
suppl.): 2125
6. V. Cernea, Ioana Brie, Maria Perde, Piroska Virag, Olga Soritau, Eva Fischer, Viorica
Nagy, O. Coza, Iolanda Sicoe, N. Ghilezan - Prediction of the response to radiotherapy
by comet assay: preliminary results in cervical tumors ECCO 13 – The European
54
cancer Conference , Paris, Franta, 30 oct-3 nov. 2005 abstract in European Journal of
Cancer –EJC Supplements, 2005, 3(2
7. Galatir L. M., Duma M.,Valoarea expresiei beta-cateninei si a gradului de diferentiere
histologica – rol prognostic in carcinoamele hepatice ? Al VII-lea Simpozion si Curs
Postuniversitar al Sectiunii Romane a IASG (International Association of Surgeons and
Gastroenterologists) , Bucuresti , 20-22 aprilie 2005
8. Claudia Ordeanu Clinical application of the different size of dose/ fraction in
brachytherapy of the cervical cancer, GEC-ESTRO Meeting, 6-7 mai 2005, Budapesta,
Ungaria
9. Cosaceanu D, R Budiu, Carapancea M, Lewensohn R and Dricu A. Molecular
Pathogenesis of Lung Cancer: Opportunities for Translation to the Clini. Ionizing
radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-
DNA-binding capacity via a P38- dependent mechanism. Poster, February 2005, San
Diego, California, USA.
10. Viorica Nagy, Claudia Ordeanu, O.Coza, N.Todor, N.Ghilezan: Quality of life in
patients with cervical cancer during concomitant radiochemotherapy, rezumat în
Abstract Book ECCO 13, 30 october-3 november 2005, Paris, EJC Supplements,
vol.3(2): 264
2006
11. Luciana Neamţiu, Daniela Coza, Florian Nicula, Ofelia Suteu, Improvement of Data
Quality in Institutional Cancer Registry by Data Linkage, The Role of Cancer Registries
in Suveillance and Cancer Care, pp. 129, Poster, octombrie 2006, Amsterdam
(Olanda)
12. Ratiu A., Anghel M.R., Coza D., Claici C.N., Cazma R., Popescu C., “Transforming
knowledge into action”, Congresul mondial de cancer UICC, 07 / 2006 Washington,
DC, USA
13. Suteu O., Nicula F., Irimie A., Lazar L., Pais R., Duma M., Neamtiu L., Coza D., Farcas
M., “Strategies of cervical cancer prevention in Cluj County, Romania”, Abstracts
55
Volume pg 440, 6th International Multidisciplinary Congress EUROGIN 2006, Paris, 04
/ 2006
14. Luciana Neamţiu, Daniela Coza, Florian Nicula, Ofelia Suteu, Improvement of Data
Quality in Institutional Cancer Registry by Data Linkage, The Role of Cancer Registries
in Suveillance and Cancer Care, pp. 129, Poster, octombrie 2006, Amsterdam
(Olanda)
15. N. Todor Estimarea intirzierii in analiza supravietuirii – la Seminarul Itinerant
“Tiberiu Popoviciu” de Ecuatii functionale, Aproximare si Convexitate, octombrie 25-
29 2006, UBB Cluj-Napoca
16. O Bălăcescu, I Neagoe, A Kauffmann, T Robert, V Lazar, G Vassal, V Cristea: in vitro
and in vivo ovarian cancer study using microarray gene expression for Cisplatin
resistance. The 17th Intrenational Congress of Anti Cancer Treatment Paris 30.01-
02.02. 2006. in abstract book 17th ICACT 2006; pp 261.
17. I Berindan Neagoe, O Balacescu, V. Cristea, E Neagoe, P Achimas, R Ola, I. Diaconu.
Angiogenesis in ovarian cancer – a molecular profile for genes involved in tumor cells
invasion. The 17th Intrenational Congress of Anti Cancer Treatment Paris 30.01-
02.02. 2006, in abstract book 17th ICACT 2006; pp 261-262
18. O. Balacescu, A Kauffmann, L Vlase, I Neagoe, S.E Leucuta. Improved
pharmacokinetics and modified pharmacogenomics of doxorubicin loaded liposomes
vs. free drug administered in mice. 33rd Annual Meeting of the Controlled Release
Society. Vienna 22-26 July 2006. pp 349
19. O. Balacescu, Neagoe I, Kauffmann A, Lazar V. Microarray pharmacogenomics of
doxorubicin entrapped PEG-liposomes in human xenografts in nude mice. The 3rd
EMBL Biennial Symposium: From Functional Genomics to Systems Biology,
Heidelberg, 14-17 october 2006. In abstract book pp 35.
20. R Budiu, Berindan-Neagoe I, Balacescu O, Dricu A, Albertioni F. Comparison of three
tryphostines for inhibiting three growth factors receptors. The 3rd EMBL Biennial
Symposium: From Functional Genomics to Systems Biology, Heidelberg, 14-17
october 2006. In abstract book pp 38.
56
21. Vlad AM, Diaconu I, Gantt K, Buiga, Neagoe Berindan I, Dricu A, Finn OJ. Tumor
antigens MUC1 and Cyclin B1 is aa markers of progession and malignancy in
endometriosis and ovarian epithelial tumors. Annual Meeting of the American
Association of Immunologists, may 12-16, Boston, 2006 Poster 141.22.
22. Cristea V, Balacescu O, Neagoe I, A. Kauffmann, V. Lazar. Microarray gene expression
for cisplatin resistance in in vitro ovarian cancer. Emerging genomic Biomarkers:
Impact on Drug Discovery and Clinical Practice; Fairmont Victoria, British Columbia,
Canada 7-11 mai 2006.
23. ID Postescu, E.Fischer-Fodor, I.Brie, M.Perde, O.Soritau, G.Chereches, C.Tatomir,
P.Virag Polyphenolic compounds antioxidative capacity of grape extracts - 3rd
Intrernational Conference on Oxidative Stress in Skin Medicine and Biology, Andros,
Grecia, 21-24 sept. 2006.
24. Pall E, Perde-Schrepler M, Soritau O, Brie I, Gocza E Comparison between two
methods of differentiation induction in a mouse embryonic stem cell line European
Summer School „Stem Cells & Regenerative Medicine”, Hydra, Grecia, 15-21 Sept
2006
25. Suteu O., Nicula F., Irimie A., Lazar L., Pais R., Duma M., Neamtiu L., Coza D., Farcas
M., “Strategies of cervical cancer prevention in Cluj County, Romania”, Abstracts
Volume pg 440, 6th International Multidisciplinary Congress EUROGIN 2006, Paris, 04
/ 2006
26. A.Filip, S.Clichici, A.Joanta, C.Tatomir, G.Chereches, C.Gherman, A.Muresan
Implication of metaloproteases and oxidative markers in the pathogenesis of
varicose disease, 13th Biennal Congress of International Society for Free Radical
Research, Davos, Switzerland,Aug.15-19 2006. Publicat in Free radical research,
2006, 40: 127
27. Claudia Ordeanu, O.Coza, S.Gavris, N.Todor, E.Szilagy, M.Bako: Impact of biological
effective dose (BED) on the survival in 261 patients treated for advanced cervical
carcinoma, poster, ESTRO 25 Conference, 8-12 octombrie 2006, Leipzig, Germania.
57
28. Ioana Berindan Neagoe - Angiogenesis in cancer biology and therapy –International
Summer School - Biogenero – 2-12 iulie 2006- Cancer Institute “Ion Chiricuta” Cluj
Napoca
2007
29. Şuteu P. Şuteu O. Nicula F. A. Coza D. Neamţiu L., Aspecte actuale de epidemiologie
descriptivă a cancerului colorectal în România, Zilele UMF „Iuliu Haţieganu” Cluj
Napoca, 7-8 dec. 2007, Vol. rez. p.41-42.
30. Teodora Sanislav, Ioan Stoian, Dorina Căpăţînă, Mihaela L. Drăgan, Luciana Neamţiu,
Florian Nicula, Ofelia Şuteu, Liana Lupşa, Data Management System for Cervical
Cancer Screening – CanScreen, Meditech 2007, Cluj-Napoca.
31. Luciana Neamţiu, Ioana Chiorean, Multiple Dynamic Programming Applied in
Cervical Screening, ENUMATH 2007, pp. 122, Final Program and Abstracts,
septembrie 2007, Graz (Austria)
32. Adela Ratiu, Milena Duma, Daniela Coza, Luciana Neamtiu, Cristina Stanescu,
Ecaterina Scortanc “assessment of childhood cancer incidence in Romania” Abstract
Book pg 171, 29th Annual Meeting of the International Association of Cancer
Registries, Ljubljana, Slovenia, 17- 20 / 09 2007
33. Liana Lupşa, Ioana Chiorean, Dorel I. Duca, Luciana Neamţiu, Special Efficient
Solutions for Multicriterial Transport Problems, ENUMATH 2007, pp. 122, Final
Program and Abstracts, septembrie 2007, Graz (Austria)
34. Daniela Coza, Florian Nicula, Ofelia Suteu, Luciana Neamţiu, Ioana Rădulescu,
Mihaela Sârbu, Lidia Lovasz, The Role of Cancer Control Department in Our
Comprehensive Cancer Center – Oncological Institute „Ion Chiricuţă”, IACR 29TH
ANNUAL MEETING, Cluj-Napoca, România, Poster, septembrie 2007, Ljubljana
(Slovenia)
35. Luciana Neamţiu, Cost-effectiveness Study for Cervical Screening Program: a
Bayesian Approach, Romanian-German (ROGER) Seminars on Approximation Theory,
Gaermania, 2007
58
36. N. Todor, Relatii intre timpii de supravietuire – la Seminarul Itinerant “Tiberiu
Popoviciu” de Ecuatii functionale, Aproximare si Convexitate, septembrie 26-29
2007, UBB Cluj-Napoca
37. Ovidiu Balacescu. Functional Genomics by microarray technologies .
Pharmacogenomics in ovarian cancer. 1st Conference in New Perspectives in Cancer
Pathology; Bucharest 24-27 mai 2007. abstract book O.P.22.
38. Ioana Neagoe. Tumor angiogenesis. 1st Conference in New Perspectives in Cancer
Pathology; Bucharest 24-27 mai 2007. abstract book I.L.1.3
39. Dumitrita Preda Rugina, Carmen Socaciu, Ioana Berindan Neagoe, Ovidiu Balacescu.
Structure and dose-related stability and antioxidant activity of catechins in abiotic vs
cell environments: HPLC fingerprint and cellular markers. 3rd International
Conference on Polyphenols and Health, 25-28 november 2007 Kyoto, Japan. Poster P
262, abstract book pag 287.
40. Eniu DT, Eniu D, Neagoe I, Brie I, Simon V, Simon S. Clinical application of 90Y Glass
microspheres in oncology: opportunities and risks. 13th general Meeting, 9 may 2007
Neuchatel. Switzerland p 29
41. Cristea V, Berindan Neagoe I, Balacescu O, Budiu R, Ola R, Bujor A, Miron N.
Multiplex laser microarray angiogenesis profiling for detection of ovarian cancer.
Poster Rio de Janeiro
42. Ioana Berindan Neagoe, Liliana Policiuc .FP 7 Health Research. Cooperation between
the EU and the Mediterranean Partners. Functional genomic platform,collaboration
possibilities. Cairo 29-30 oct 2007.
43. Ovidiu Balacescu. Angiogenesis and angiomics in cancer biology and therapy
use of microarray technology. Functional Genomics in Cancer Biology and Therapy-
Biogenero; 27-28 nov 2007 Cluj Napoca.
44. Ioana Berindan Neagoe - The future of therapy in cancer – dr. Ioana Berindan
Neagoe – Cancer Institute Cluj Napoca - International Conference - FUNCTIONAL
GENOMICS IN CANCER BIOLOGY AND THERAPY 28-31 May 2007 Cancer Institute Cluj
Napoca Romania
59
45. Ioana Berindan Neagoe Functional genomics studies related to bioethical conditions
in European Community – International Workshop - Functional Genomics Studies
And Their Validation In Cancer Diagnosis And Therapy - Bioethical Conditions And
European Legislation, Canacer Institute – 4-6 dec 2007
46. Loredana Balacescu- Bioethics in genomics and bioinformatics International
Workshop - Functional Genomics Studies And Their Validation In Cancer Diagnosis
And Therapy - Bioethical Conditions And European Legislation, Canacer Institute – 4-
6 dec 2007
47. O.Balacescu - Microarray technologies in genes panels definiton in ovarian cancer
evolution- International Conference - FUNCTIONAL GENOMICS IN CANCER BIOLOGY
AND THERAPY 28-31 May 2007 Cancer Institute Cluj Napoca Romania
48. Soimita Suciu, A.Muresan, I.D.Postescu, D.Daicoviciu, P. Virag, O.Barbos, I.V.Cernea,
In vitro and in vivo studies on the antitumor efects of polyphenols from vitis vinifera
c.v. Burgund mare , Recas, Romania 3-rd International Conference on Polyphenols
and Health, 25-28 nov.2007, Kyoto, Japonia
49. Ioana Brie, Maria Perde, Piroska Virag, Eva Fischer-Fodor, “Relationship between
cellular radio-sensitivity evaluated by Comet Assay and clinical outcome of patients
with cervix carcinoma treated by radiotherapy” A VII-a Conferinta Internationala de
Comet Assay Universitatea din Ulster, Coleraine, 24-27.06.2007
50. Eva Fischer Fodor, I.D.Postescu, Piroska Virag, Corina Tatomir, M.Tamas, Ioana Brie,
Maria Perde Antimitotic and Antioxydant Effects of Alkaloids from Solanaceae and
Triterpenes from Ericaceea, 2nd International Symposium on Nutrition, Oxygen
Biology and Medicine, Sorbonne, Paris, Franta, 11-13 Apr.2007, Abstract volume:
p.79
51. Piroska Virag, I.D. Postescu, Olga Soritau, Corina Tatomir, Eva Fischer-Fodor,
Gabriela Chereches. Protective Effects of a grape-seeds Hydroalcoholic Extract
(BMR) in the Treatment with Doxorubicin 2nd International Symposium on Nutrition,
Oxygen Biology and Medicine, Sorbonne, Paris, Franta, 11-13 Apr.2007, Abstract
volume
60
52. Bianca Moldovan, Luminita David, Eva Fischer Fodor, Ion Grosu New Solasodine
Derivates with Potential Anticancer Activity SFC07 Congress "Chemistry of the future,
the Future of Chemistry", Paris, 2007, Abstract Book: p54-55,
53. Simina Dreve, Adriana Muresan, Adriana Filip, Doina Daicoviciu, Simona Clichici,
Maria Perde-Schrepler, Rodica Mariana Ion, E.Indrea, TD Silipas Cytotoxic effects of
chitosan-based formulations: in vitro and in vivo experiments EuroNanoForum 2007,
Nanotechnology in industrial applications- European and International Forum on
Nanotechnology, Dusseldorf, 19-21.06.2007, Abstract book, p.311
54. Lung-Illes V, Foris V, Brie I, Soritau O, Perde M, Virag P, Fischer E In vitro evaluation
of lymphocytes radiosensitivity in patients with cervix carcinoma using micronuclei
and comet assay 18th European Students’ Conference, Promising Medical Scientists
Willing to Look Beyond, Charite- Universitatsmedizin, Berlin, Germany, 7-11Oct.
2007. Abstract book, p.150.
55. V. Foris, I. Brie, O. Soritau, V. Piroska, M. Perde, E. Fischer Evaluation by comet
assay of lymphocytes’ in vitro radiosensitivity in healthy women and patients with
cervix carcinoma - 14th International Student Congress of Medical Sciences,
University Medical center Groningen, The Netherlands, 6-9 Iun. 2007, Abstract book,
p. 268
56. Radiobiology Research Center in Cancer Institute Cluj, Romania, V. Cernea, Ioana
Neagoe, Ioana Brie, O. Balacescu Olga Soritau, Maria Perde, A. Irimie,
Experimentelle Strahlentherapie und Klinische Strahlenbiologie, Proceedings des 16.
Symposiums, Dresden, 2007 ISSN 1432-846XX, p. 28-31
57. Cucuianu A. Targeting epigenetics and other pathways in the treatment of
myelodysplastic syndromes.18th Annual Congress of the Greek Society of
Hematology, November 14-17, 2007, Thessaloniki, Greece
2008
58. Neamţiu L., Chiorean I., Lupşa L., Model of Multiple Lexicographical Programming
Applied in Cervical Cancer Screening, în Kunich Karl, Of G., Steinbach O. (Editors),
Numerical Mathematics and Advanced Applications, Springer-Verlag, 2008, p. 91-98.
61
59. Radu Lupşa, Liana Lupşa, Luciana Neamţiu, An Optimal Model to Solve the Transport
Problem for Mammography Screening, AQTR, Cluj-Napoca, Romania, 2008.
60. Luciana Neamţiu, Ioan Stoian, Teodora Sanislav, Dorina Căpăţînă, Florian Nicula,
Ofelia Şuteu UICC World Cancer Congress, Geneva, Elveţia, CANSCREEN – FAIL-SAFE
SYSTEM FOR DIAGNOSIS QUALITY CONTROL IN CANCER SCREENING, publicată ca şi
rezumat în Supplement of the International Journal of Cancer, 2008.
61. Liana Lupşa, Dorel I. Duca, Ioana Chiorean, Luciana Neamţiu, A Model of Dynamic Bi-
level Transportation Problem, 6th INTERNATIONAL CONFERENCE ON APPLIED
MATHEMATICS Baia-Mare, Romania, 2008.
62. Ioana Chiorean, Liana Lupşa, Luciana Neamţiu, Markov Models for the Simulation of
Cancer Screening Process, ICNAAM 2008 (International Conference on Numerical
Analysis and Applied Mathematics), Grecia, 2008.
63. Liana Lupşa, Lucia Blaga, Luciana Neamtiu, A Model of a Lexicographic Bi-criteria
Dynamic Transport Problem, The Twelfth International Conference on Applied
Mathematics and Computer Science, Baisoara, Romania, 2008.
64. Albu C. Bardoş M. Şuteu O. Vladu C. Campania de informare, educare, schimbare de
comportamente din cadrul programului de screening organizat pentru depistarea
cancerului de col uterin – parte a componentei de prevenţie secundară din cadrul
Planului Naţional de Cancer. Conferinţa naţională cu participare internaţională –
Calitatea europeană în medicina familiei. 7-8 nov. 2008, Bucureşti. Vol. Rez. P. 34.
65. FA. Nicula. Neamţiu L. Şuteu O. Păiş R. Model de organizare a unui program regional
de screening al cancerului de col uterin – experienţa pilotului regional Cluj după
prima rundă de 5 ani de screening organizat în perioada 2003-2007. Conferinţa
Naţională de SănătatePublică cu participare internaţională – Prezent şi viitor în
Sănătatea Publică din România. 12-14 nov. 2008, Timişoara. Vol. rez. P.39.
66. Coza D. Claici C. Nicula F.A. Neamţiu L. Şuteu O. Registrul de cancer în România – la
răscruce de drumuri. Conferinţa Naţională de SănătatePublică cu participare
internaţională – Prezent şi viitor în Sănătatea Publică din România. 12-14 nov. 2008,
Timişoara. Vol. rez. p. 40.
62
67. P. Virag, M. Perde-Schrepler, I. Brie, E. Fischer-Fodor, O. Soritau, C. Tatomir, G.
Chereches, I.D. Postescu. Comparative study of two methods of evaluation genotoxic
effects of environmental heavy metals on normal cells, First International Conference
on Environmental Stressors in Biology and Medicine, University of Siena, Siena, Italy,
june 4-6, 2008: 88.
68. V. Foris, V. Lung Illes, C. Tomuleasa, E. Fischer Fodor, P. Virag, M. Perde, O. Soritau,
V. Nagy, V. Cernea: Comet assay and micronuclei assay as tools for studying the
relationship between chronic exposure to heavy metals and genomic lesions, 16th
Annual International Ain Shams Medical Students’ Congress, 16th-18th February
2008, Cairo, Egypt.
69. S. Clichici, M. Perde-Schrepler, A. Filip, D. Daicoviciu, P. Virag, E. Fischer-Fodor, I.
Brie, R. Mariana Ion, C. Loghin, A. Muresan. In vitro and in vivo assessment of the
efficiency of phtotodynamic therapy with tetrasulphophenil-porphyrin, Fiziologia
physiology, vol 18, 2 (58), Congress of the Romanian Society of Physiological
Sciences, Cluj-Napoca, Romania, june 5-7, 2008:17-18.
70. I.D. Postescu, P. Virag, M. Achim, C. Tatomir, E. Fischer-Fodor, O. Soritau.
Modulatory activity of antioxidants in associated treatments with Doxorubicin,
Fiziologia physiology, vol 18, 2 (58), Congress of the Romanian Society of
Physiological Sciences, Cluj-Napoca, june 5-7, 2008:59.
71. C.I. Tomuleasa, O. Soritau, D.R. Ciuca, S. Susman, E. Pall, E. Fischer-Fodor, M.
Perde-Schrepler, P. Virag, I. Brie, V. Lung-Illes, V. Foris. Immunocytochemical
characterization of human mesenchymal stem cells, Fiziologia physiology, vol 18, 2
(58), Congress of the Romanian Society of Physiological Sciences, Cluj-Napoca, june
5-7, 2008:17-18.
72. C.Tatomir, G.Chereches, D. Daicoviciu, I.D.Postescu: Antioxidant and antiinvasive
activity of grape seed (vitis vinifera) extract. The 10-th Congress of the Romanian
Society of Physiological Sciences, Cluj-Napoca, 5-7 June, 2008, Fiziologia, 2008,18
(abstract)
63
73. T. Dicu, V. Foris, I. Brie, I. V. Cernea, I. D. Postescu, Protective effects of L-cysteine
against 60 Co X-rays induced damages in human lymphocytes, Fiziologia physiology,
The 10-th Congress of the Romanian Society of Physiological Sciences, Cluj-Napoca,
june 5-7, 2008, 22.
74. A.Mureşan, Ş. Suciu, I. D. Postescu, G. Damian, D. Colcear, N. Pop, M. Paul,
Experimental study regarding the antioxidant and antitumor activity of naturally
occuring polyphenols, Fiziologia physiology, The 10-th Congress of the Romanian
Society of Physiological Sciences, Cluj-Napoca, june 5-7, 2008, 50.
75. G. Damian, D. Petrişor, V. Miclăuş, C. Cimpoiu, A. Hosu, I. D. Postescu, EPR
investigations of antioxidant activity of some grape skin and seed extracts, Fiziologia
physiology, The 10-th Congress of the Romanian Society of Physiological Sciences,
Cluj-Napoca, june 5-7, 2008, 20.
76. L. I. Sabău, D. Daicoviciu, A. Mureşan, I. D. Postescu, R. Moldovan, The effects of red
grapes polyphenols in female rats with experimentally induced menopause, Fiziologia
physiology, The 10-th Congress of the Romanian Society of Physiological Sciences,
Cluj-Napoca, june 5-7, 2008, 64.
77. I.Chiş, R. Simedrea, M. I. Ungureanu, A. Mureşan, N. Giurgea, I. D. Postescu, A.
Marton, N. Decea, Liver tissue oxidative stress and the role of polyphenols
administration in a rat model of diabetes mellitus, Fiziologia physiology, The 10-th
Congress of the Romanian Society of Physiological Sciences, Cluj-Napoca, june 5-7,
2008, 16.
78. C.Tatomir, I.D.Postescu, Virag P., T.Dicu, E Fischer-Fodor, I. Brie, M.Perde-
Schrepler, G.Chereches. In vitro cytoprotective and radioprotective effects of a whey
protein isolate, (WPI). The 4-th Conference of the Romanian Association of Medical
Laboratories, Cluj-Napoca,18-21 iunie, 2008, Rev.Rom Med. Lab.11(2), supl.27-28,
2008
79. L.Sabau, G.Damian, D.Daicoviciu,A.Muresan, I.D.Postescu, D.Mihu,C.Mihu, In vivo
study regarding antioxidant effect of a grape polyphenol extract using
64
biochemicaland FTIR methods, 3-rd Internat Symp.Advanced spectroscopy on
biomedical and nanostructured systems, Cluj-Napoca, sept 7-10, 2008
80. I. Haiduc, I. Silaghi Dumitrescu, Z. Garban, E. Fischer Fodor, R. Silaghi Dumitrescu,
Metallomics. Metal Elements in Environment, Medicine and Biology, ISSN 1583-4204,
Tome VIII: Proceedings of the 8th International Symposium on Metal Elements in
Environment, Medicine and Biology, Romanian Academy, Timisoara, 2008.
81. E. Fischer Fodor, N. Miklasova, P. Virag, C. Tatomir, I. Brie, M. Perde, V. Cernea, L.
Silaghi Dumitrescu, Biologic evaluation of platinum and palladium complexes using
the static cytometry. Metal Elements in Environment, Medicine and Biology, ISSN
1583-4204, Tome VIII: Proceedings of the 8th International Symposium on Metal
Elements in Environment, Medicine and Biology, Romanian Academy, Timisoara,
2008.
82. M. Perde-Schrepler, I. Brie, P. Virag, I.D. Postescu, O. Soritau, E. Fischer-Fodor, G.
Chereches, C. Tatomir, S. Dreve. Effects of chitosan nanoparticles on the uptake and
phototoxicity of delta-aminolevulinic acid. Abstracts of the 34th Meeting of the
American Society for Photobiology, 2008: 65-66.
83. E. Fischer-Fodor, M. Perde-Schrepler, I. Brie, P. Virag, C. Tatomir, N. Moldovan, L.
Silaghi-Dumitrescu. Antiproliferative Effect and Genotoxicity of Novel Synthesized
Palladium Complexes with Organoarsine Ligands, Quatrieme conference
internationale sur les metaux et la genetique, Faculte de Pharmacie, Universite Paris
Descartes, Paris, 21-24 juillet, 2008: 48.
84. C. I. Tomuleasa, O. Soriţău, V. Foris, V. Lung-Illes, I. Brie, E. Fischer-Fodor, M. Perde-
Schrepler, P. Virág, I.D. Postescu, G. Cherecheş, D. Piciu: Osteoblast differentiation
and immunochemical characterisation of human mesenchymal stem cells, Liječnički
Vjesnik, 2008, 130, Suple. 5, 66.
85. V. Nagy, I. Brie, A. Rancea, N. Todor, C. Ordeanu, O. Coza, A. Traila, M. Perde-
Schrepler, P. Virag, E. Fischer-Fodor, Relationship between in vitro tumor cells
radiosensitivity evaluated by Comet Assay and tumor response to radiochemotherapy
65
in partients with cervix carcinoma, ASTRO 27 Congress, sept 14-18 2008, Goteborg,
Sweden.
86. N. Todor, I. Brie, V. Nagy, M. Perde, G. Saplacan, A computerized morphometric
system for comet assay, Proceedings of the 8th international conference on technical
informatics – CONTI- Timiosara, 5-6 iunie 2008, Automation and applied informatics,
ISSN 1844-539X: 183-186.
87. Cucuianu A. The 2008 WHO Classification of Acute Myeloid Leukemias. The impact
on diagnosis and therapeutic decision making. 2nd Congres of the Romanian
Association of Medical laboratories with International Participation, 25-27 June 2010,
Mamaia, Romania
88. Patiu M., Bacarea A.,Dascalu A., Nicorici C., Cucuianu A. : Myeloid sarcoma. Report of
three cases and rewiew of the literature. 4thRAML Conference with International
Participation 18-21 june 2008 Cluj-Napoca Romania –Abstract published in Revista
Romana de Medicina de Laborator, vol 11,nr 2, iunie 2008 Supliment pg 16-17
89. O. Balacescu, I Neagoe, I Coman, N Crisan, B. Feciche, L. Balacescu, O. Tudoran, C.
Burz, R Suharoschi. A good correlation between DD3PCA, hTERT, GDF15 and PSME
gene expression for prostate cancer diagnosis. International Congress for Anticancer
Treatment (ICACT) Paris, 5-8 februarie 2008. Poster PO 130, p224.
90. I Neagoe, V.Cristea, O. Balacescu, O.Tudoran, R.Budiu, R.Ola, L.Balacescu, A.Bujor,
N.Miron. Multiplex laser based microarray angiogenesis profiling for detection of
ovarian cancer. International Congress for Anticancer Treatment (ICACT) Paris, 5-8
februarie 2008. Poster PO 142, p251.
91. O.Tudoran, I Neagoe, O. Balacescu, R.Budiu, P.Achimas, V.Cristea The evaluation of
molecular profiling of angiogenesis markers in patients with ovarian cancer.
International Congress for Anticancer Treatment (ICACT) Paris, 5-8 februarie 2008.
Poster PO 155, p258.
92. L.Balacescu, O. Balacescu, I Neagoe, V.Cristea, A.Kauffmann, V.Lazar Apoptosis
inhibition by tumor angiogenesis mechanisms in ovarian cancer. Bioinformatic study
66
involving microarray gene expression. International Congress for Anticancer
Treatment (ICACT) Paris, 5-8 februarie 2008. Poster PO 241, p334
93. C.Burz, C.Tanaselia, I Neagoe, O. Balacescu, M.Ursu, A.Gog, L.Vlase, D.Leontin,
M.Chintoanu, S.E.Leucuta, V.Cristea, Clinical Pharmacokineticsof Oxaliplatin in colon
cancer patients International Congress for Anticancer Treatment (ICACT) Paris, 5-8
februarie 2008. Poster PO 68, p206
94. C Burz, B.I. Neagoe, O. Balacescu, O. Tudoran, S. Leucuta, V. Cristea, A. Irimie
Genomic analysis of gene involved in platinum compound resistance. Annals of
Oncology, Volume 19, Supplement 8, September 2008 viii55 - abstract publicat in
revista ISI.
95. Neagoe Berindan Ioana, Balacescu O, Tudoran Oana, Dronca Eleonora, Burz
Claudia, Irimie Al, Cristea V –Terapia antiangiogenica prin utilizarea ARN interferentei
in controlul postranscriptional al expresiei genelor. Comunicata - A 38-a conferinta
anuala de Imunologie, 24-26 septembrie 2008, Busteni, Romania (pag 68-69).
96. Nedelea Irena , Neagoe Berindan Ioana , Cristea V, Burz Claudia , Seiceanu Andrada,
Balacescu O, Balacescu Loredana, Tudoran Oana, Dronca Eleonora – Evaluarea prin
protein array a citokinelor proinflamatorii in cancerul pancreatic versus pancreatita
cronica Comunicata – A 38-a conferinta anuala de Imunologie, 24-26 septembrie
2008 , Busteni, Romania (pag 69-70).
97. Burz Claudia, Neagoe Berindan Ioana, Balacescu O, Nedelea Irena, Tanasila C, Ursu
M, Vlase L, Leucuta S, Irimie A, Cristea V. Oxaliplatin in cancerul colorectal- mecanism
de actiune si parametrii farmacologici. Comunicata la A 38-a conferinta anuala de
Imunologie, 24-26 septembrie 2008 , Busteni, Romania (pag 70- 71).
98. Irena Nedelea, Cristian Nicolae Manea , Claudia Burz, Dan Stanca, Ovidiu Mestes ,
Ovidiu Balacescu, Ioan Coman, Victor Cristea. Molecular mechanisms of chronic
kidney graft loss by interstitial fibrosis and tubular atrophy, Comunicata -The XXth
International Symposium of Morphological Sciences (ISMS), Timisoara, 2008 in
abstract book.
67
99. Irena Nedelea, Claudia Burz, Ioana Neagoe, Loredana Balacescu, Ovidiu Balacescu,
Oana Tudoran, Eleonora Dronca, V.Cristea. Protein array evaluation of
proinflammatory cytokines in pancreatic cancer versus chronic pancreatitis,
Comunicata International Conference of cellular and tissue comparative pathology,
Cluj Napoca, 2008 in abstract book.
100. O. Balacescu, I. Neagoe, N. Crisan, B. Feciche, L.Balacescu, O.Tudoran, A. Irimie,
C. Burz, R. Suharoschi, I. Coman, - Comunicata Aplicatiile reactiei de PCR cantitativ
(QRT-PCR) pentru diagnosticul molecular in cancerul de prostata – Simpozion
National VIASAN CEEX ( Modulul I) , 28-30 septembrie 2008, Sinaia, Romania 59 –
poster
101. Sebestyen Gh., Saplacan G., Rusu M.,Todor N.: Food production monitoring
system for quality and traceability assurance, MicroCAD2008- Nemzetközi
Tudományos Konferencia - International Scientific Conference, pp.125-132, 20-21
March 2008, Miskolc, HUNGARY
102. Gheorghe Sebestyen , Sergiu Nedevschi, Gavril Saplacan , Mihai Cerghizan ,
Nicolae Todor and Mircea Rusu, Towards a Traceability Solution on the Food Supply
Chain, CONTI’2008 The 8th INTERNATIONAL CONFERENCE ON TECHNICAL
INFORMATICS, pp. 121-126, 5-6 June 2008, Timisoara, Romania
103. Nicolae Todor, Saplacan Gavril, Dan Radulescu: semiparametric methods to
evaluate the relationship between survival times, sectiunea poster, International
Biometric Conference, 13 – 18 July 2008, Dublin, Irlanda
104. Gheorghe Sebestyen, Sergiu Nedevschi, Gavril Saplacan, Mihai Cerghizan,
Nicolae Todor, Mircea Rusu: FOODTRACE-Food Quality Control and Traceability
Framework - Scientific Bulletin of The “POLITEHNICA” University of Timisoara,
Romania; Tom 53(67), Fascicola2, 2008, ISSN 1224-600X, pp 115-122
2009
105. Luminiţa Leluţiu “The 12th Romanian-Hungarian Meeting of Pediatric Oncology”,
23-24 octombrie 2009, Cluj-Napoca; lucrarea prezentata: BCR-ABL Positive Chronic
68
Myeloid Leukemia in Infancy – G. Popa, Cristina Blag, Dana Olosutean, Mirela Marian,
Manuela Sfichi, Anca Ilea,;
106. Guran Adriana Mihaela, Moldovan Grigoreta Sofia, Neamtiu Luciana, O abordare
centrata pe utilizator in dezvoltarea unui sistem inteligent pentru generarea
Registrelor Nationale de Cancer, Conferinta Nationala de Interactiune Om-Calculator,
Matrix Rom, Editor: Dorian Gorgan, Adriana-Mihaela Guran, 2009, P. 77-83.
107. Rodica Pais, Mihaela Galatar, Luciana Neamtiu, Ioana Neagoe, Ovidiu Balacescu,
Florian Nicula HPV PCR and liquid based cytology use in cervical cancer preinvasive
lesions triage / poster , Zilele IOCN , Cluj Napoca, 30 Septembrie 2009 - 3 Octombrie
2009 , CLuj Napoca
108. 2. Florian Al. Nicula, Luciana Neamtiu, Mihaela Galatar, Rodica Pais, Ofelia
Suteu “ Ion Chiricuta “ Cancer Institute Department of Prevention and Cancer
Control- one of the oldest cervical cancer prevention management units in Europe,
Zilele IOCN , Cluj Napoca, 30 Septembrie 2009 - 3 Octombrie 2009 , CLuj Napoca
109. Daniela Coza1, Florian Nicula1, Luciana Neamţiu1, Ofelia Şuteu1,2, Lidia
Lovasz1, Mihaela Sîrbu1,AnnaMaria Marton1 LOCUL REGISTRULUI DE CANCER ÎN
ISTORIA INSTITUTULUI ONCOLOGIC “ION CHIRICUŢĂ” Zilele IOCN , Cluj Napoca, 30
Septembrie 2009 - 3 Octombrie 2009 , CLuj Napoca
110. Luciana Neamţiu, Florian Nicula Sisteme informatizate pentru management de
date în programul de control al cancerului- Zilele IOCN , Cluj Napoca, 30 Septembrie
2009 - 3 Octombrie 2009 , CLuj Napoca
111. Coza D. Nicula F. Neamţiu L. Şuteu O. Sârbu M. Lovasz L. Marton A. The role of
NW Regional Cancer Registry from Oncological Institute „Prof. Dr. I. Chiricuţă” Cluj, in
cancer control. Workshop: Priorities for the fight against cancer: responses of the
national and regional healthcare systems. The Latin Association for Health Systems
Analyses. 28-30 May 2009, Constanţa. Vol. Rez. p. 24.
112. Luciana Neamtiu: Modèle de gestion des données dans un Registre Cancer
Régional: le Registre Cancer de la Région Nord-Ouest, prezentare orala, in cadrul
69
Atelier de l’ALASS Priorités dans la lutte contre le cancer: réponses des systèmes
sanitaires régionaux et nationaux, Constanta (Mamaia) Roumanie, 29 - 30 mai 2009;
113. Coza D. Nicula F.A. Neamţiu L. Şuteu O. First year of planning and
implementation of regional cancer registration in North-West region of Romania. 3rd
International cancer Control Congress, 8-11 november 2009, Cernobbio, Como, Italy.
Vol. Rez. p.44.
114. Nicula F. Coza D. Neamţiu L. Claici C. Ungureanu C. Cancer control in Romania –
regional traditional resources and today strategies in cancer registry and screening.
3rd International cancer Control Congress, 8-11 november 2009, Cernobbio, Como,
Italy. Vol. Rez. p. 44
115. Claici C. Ungureanu C. Chicin G. Coza D. Brehar- Cioflec D. Cozma R. Domnariu C.
Cancer surveillance and control system in Romania. 3rd International cancer Control
Congress, 8-11 november 2009, Cernobbio, Como, Italy. Vol. Rez. p. 44-45
116. Luciana Neamtiu, Daniela Coza, Florian Nicula: Computerized Sources of Data –
a Useful Tool for Cancer Registration in the Nord-West Regional Cancer Registry,
poster in cadrul 3rd International Cancer Control Congress, Cernobbio, Italia 8-11
nov. 2009
117. Ronco G. Balegooijen M. Becker N. Chil A. Fender M. Giubilato P. Kurtinaitis J.
Lancucki L. Lynge E. Morais A. O’Reilly M. Sparen P. Suteu O. Rebolj M. Veerus P.
Primic Zakelj M. Anttila A. Extension and process performance of European cervical
cancer screenning programmes. The 25th International Papillomavirus Conference,
May 8-14 2009, Malmö, Sweden.
118. Claici C. Nicula F. Coza D. Fekete E.J. Anticancer strategies – Romanian resources
for action and controversies. Vol. rez. P.115-116. A XXXIV-a Întâlnire Grell, Lugano,
Elveţia, 20-22 mai 2009
119. Daniela Coza. Ratiuni si actiuni in organizarea Registrului National al Cancerelor
la Copil.The 12-th Romanian-Hungarian Meeting of Pediatric Oncology, 23-24
October 2009, Cluj Napoca
70
120. Camelia Nicoleta Claici, Florian Alexandru Nicula, Daniela Coza, Edit Julia Fekete,
“Anticancer Strategies – Romanian Resources for Action and Controversies”, Volum
de rezumate, pag 115-116, a XXXIV- a intalnire GRELL (Grupul Registrelor Cancer de
Limbă Latină), Lugano, 20-22 mai 2009
121. I.D.Postescu, T.Dicu, G.Chereches, A.Filip, C.Tatomir, M.Perde Schrlepler: A
procedure to measure the antioxidant properties of polyphenolic compounds with
DPPH∙ radical assay; biological applications.II nd International Conference of
Oxidative Stress „Havana- Redox 2009, Havana, Cuba, January 29-31, 2009, Rev.
Cubana Farm. 43, (supple 1), 2009, p.20
122. A. Filip, S. Clichici, R.M. Ion. D. Daicoviciu, T. Mocan, C. Tatomir, L. Rogojan, D.
Olteanu, A. Muresan: Self-organized functional materials in photodinamic therapy
cancer, Simpozionul al VII-lea "Mecatronica si inginerie mecanica, microtehnologii si
materiale noi" Revista Romană de Mecanică Fină, Optică şi Mecatronică, Tirgoviste
2009 (rev. Cat.B) ISSN-1584-5982
123. A.-V. Sitar-Tăuţ, M. Cebanu, O. Soriţău, C. Stugren, D. Pop, D. T. Zdrenghea: A
comparison between adhesion molecules (as markers of inflammation) in identifying
cardiovascular disease in postmenopausal women, 2009, Endocrine Abstracts, 20,
P366.
124. E. Fischer Fodor, R. Buiga, D. Pelau, C. Lisencu, P. Virag, C. Tatomir, O. Soritau,
In vitro chemosensitivity testing of tumor cells treated with platin-based drugs. Metal
Elements in Environment, Medicine and Biology, Tome IX, Romanian Academy, 2009:
116-121, ISSN 1583-4204
125. V. Foris, C. Tomuleasa, O. Soritau, V. Lung-Illes, I. Brie, V. Cernea: Comet Assay
as a tool for evaluating radiosensitivity of Mesenchymal Stem Cells, 2nd International
Medical Congress “ASKLEPIOS” 7th-10th May 2009, Sibiu, Romania.
126. V. Foris: Evaluation of stem cells radiosensitivity on ionizing radiation, 4th
International Medical Students' Congress in Novi Sad 16th-19th July 2009, Novi Sad,
Serbia.
71
127. Muresan, A., Suciu, S., Ghibu, S., Daicoviciu, I.D Postescu, I.D., Login, C.The
effect of red grapes polyphenols on antioxidant enzymes in rats exposed to hypobaric
hypoxia, 11-th Regional conf. On Enviroment and Health, 15-16, Mai 2009, Szeged,
Hungary
128. A.Mureşan, S. Suciu, S. Ghibu, D. Daicoviciu, I. D. Postescu, C. Login,
Experimental study regarding the effects of hypobaric hypoxia on some antioxidant
enzymes, A 23-a Conferinţă Naţională a Societăţii Române de Ştiinţe Fiziologice,
Fiziologia physiology, 2009, Suppl, ISSN 1223-2076, 34-35.
129. S. Suciu, A. Mureşan, D. Daicoviciu, S. Clichici, I. D. Postescu, A. Ceban,
Experimental study on the antioxidant effects of polyphenols in Ehrlich ascites
carcinoma, A 23-a Conferinţă Naţională a Societăţii Române de Ştiinţe Fiziologice,
Fiziologia physiology, 2009, Suppl, ISSN 1223-2076, 47.
130. C. Cuceu, D. Ciorba, E. Fischer-Fodor, C. Cosma, D. Marcu, Senzitivitatea de
expunere la Radon si cancerul pulmonar, Zilele Institutului Oncologic „Prof Dr. Ion
Chiricuta”- 80 de ani de lupta impotriva cancerului, 2009, 35.
131. C. Tomuleasa, O. Soritau, E. Pall, S. Susman, D. Rus, C. Mihu, R. Buiga, V. Foris,
C. Iancu: Isolation of liver cancer stem cells a hepatocellular carcinoma biopsy. Zilele
Institutului Oncologic “Prof.Dr.Ion Chiricuta”, 80 de ani de lupta impotriva cancerului,
1-3 oct 2009
132. D.Rus, O. Soritau, S. Susman, C. Mihu : Celulele stem placentare : comoara ce se
arunca. Zilele Institutului Oncologic “Prof.Dr.Ion Chiricuta”, 80 de ani de lupta
impotriva cancerului, 1-3 oct 2009
133. E. Fischer-Fodor, P.Virag, C. Tatomir, L. Silaghi-Dumitrescu: Organometal
compounds applied as radiopharmaceuticals. Zilele Institutului Oncologic
“Prof.Dr.Ion Chiricuta”, 80 de ani de lupta impotriva cancerului, 1-3 oct 2009
134. V. Foris, T.Dicu, I.D.Postescu, I.Brie, E. Fischer-Fodor, V.Cernea, M.Moldivan, C.
Cosma: The effect of a Grape Seed Extract on Radiation-Induced DNA Damage in
Human Lymphocites. Zilele Institutului Oncologic “Prof.Dr.Ion Chiricuta”, 80 de ani de
lupta impotriva cancerului, 1-3 oct 2009
72
135. G.Chereches, C.tatomir, D.Daicoviciu, I.D.Postescu: Antioxidant activity of a
natural Red-Grape Seed Extract (BMR). Zilele Institutului Oncologic “Prof.Dr.Ion
Chiricuta”, 80 de ani de lupta impotriva cancerului, 1-3 oct 2009
136. M. Perde-Schrepler, O.Barbos, I.Brie, C. Tatomir, I.D.Postescu: Protective effects
of Calluna Vulgaris on UVB-irradiated keratinocytes. Zilele Institutului Oncologic
“Prof.Dr.Ion Chiricuta”, 80 de ani de lupta impotriva cancerului, 1-3 oct 2009
137. O. Barbos, P.Virag, T.Dicu, C. Tatomir, E. Fischer-Fodor, I. Brie, M. Perde-
Schrepler, V.Cernea, I.D.Postescu: The cyto and radioprotective effects of a Whey
Protein Isolate. Zilele Institutului Oncologic “Prof.Dr.Ion Chiricuta”, 80 de ani de lupta
impotriva cancerului, 1-3 oct 2009
138. O.Soritau, V.Foris, D.Todea, I. Brie, V.Lung-Ilies, C. Tomuleasa, O.Barbos,
B.Pitea, T.Pop, V.Cernea, R.Badea; In vitro study of tumor angiogenesis in
hepatocarcinoma. Zilele Institutului Oncologic “Prof.Dr.Ion Chiricuta”, 80 de ani de
lupta impotriva cancerului, 1-3 oct 2009
139. I.-C.Brie, V. Nagy, N. Todor, P. Virag, M. Perde-Schrepler, E. Fisher-Fodor, V.
Foris, O. Coza, G. Kacso, C. Ordeanu, A. Rancea: Determinarea preterapeutica a
radiosensibilitatii celulelor tumorale prin testul cometei – metoda de predictie a
raspunsului clinic la radio-chimioterapie in cancerul de col uterin, Conferinta
Societatii Romane de Radioterapie si Zilele medicale ale Institutului Oncologic
“Prof. Dr. Al. Trestioreanu” Bucuresti, Poiana Brasov, 17-19. 09. 2009.
140. I.-C. Brie, V. Nagy, N. Todor , P. Virag, M. Perde-Schrepler, E. Fisher-Fodor, V.
Foris, O. Coza, G. Kacso, C. Ordeanu, A. Rancea: Radiosensibilitatea celulara
intrinseca – factor de predictie a raspunsului la radiochimioterapie in cancerul de col
uterin, Conferinta Nationala “Zilele Oncologiei Ieşene” – Progrese in terapiile
cancerului: tendinte, oportunitati, controverse, Iaşi, 3 – 5 decembrie 2009.
141. Cucuianu A, Precup R. A Hypothetical Mathematical Model of Acute Myeloid
Leukemia Pathogenesis. Poster Presentation, 14th European Hematology Association
Congress, Berlin, 2-6 Iunie 2009
73
142. Mariana Patiu, Selicean Elena-Cristina, Filipas Cristina, Nastase Violeta, Cucuianu
Andrei: Pure red cell aplasia in immunosuppressed transplant recipients.Case report
and literature review. 1 st Congres of the Romaniana Association of Medical
laboratories with International Participation, 24-27 June 2009, Tg Mures, Romania
abstract in Revista Romana de Medicina de Laborator.vol 15 nr 2 iunie 2009, pg 18
143. Mariana Patiu, Selicean Elena-Cristina, Filipas Cristina, Nastase Violeta,Cucuianu
Andrei: Pure red cell aplasia in immunosuppressed transplant recipients.Case report
and literature review. 1 st Congres of the Romaniana Association of Medical
laboratories with International Participation, 24-27 June 2009, Tg Mures, Romania
abstract in Revista Romana de Medicina de Laborator.vol 15 nr 2 iunie 2009, pg 18
144. Patiu M., Selicean C., Filipas C.,Nastase V., Cucuianu A. : Pure red cell aplasia in
immunossupressed renal transplant recipients. Case report and literature review. 1th
Congress of the Romanian Association of Medical Laboratories with International
Participation 24-27 june 2009 Tg Mures Romania, Abstract Published, . Revista Romana
de Medicina de Laborator, vol 15, nr 2, iunie 2009 supliment pg 18-19
145. Ciocanea C.I., Neagoe Berindan I., Balacescu O., Tudoran O., Balabescu L.,
Chiorean R., Irimie A., Cristea V. Molecular profiling of genes involed in angiogenesis
mechanism in ovarian borderline tumors using Agilent microarray technology,
Comunicata Medicalis Abstract Book, pag. 13, Cluj-Napoca, 14-17 may 2009.
146. Chiorean R., Balacescu O., Tudoran O., Balacescu L., Ciocanea C., Crisan N., Irimie
A., PCR Array analysis of angiogenic transcription profile in blood sample for prostate
cancer, Comunicata Medicalis Abstract Book, pag. 15, Cluj-Napoca, 14-17 may 2009.
147. Pileczki V., Kaucsar, T., Braicu C., Balabescu O., Cristea V., Irimie A., Optimization
of short interfering RNA (siRNA) trabsfection in Hs578T human breast cancer cell
lines for cancer therapy, Comunicata Medicalis Abstract Book, pag. 35, Cluj-Napoca,
14-17 may 2009.
74
148. Kaucsar T., Pileczki V., Braicu C., Balacescu O., Stugren C., Irimie A., Cristea V.,
Application of RNA interference in angiogenesis inhibition in breast cancer cell lines,
Comunicata Medicalis Abstract Book, pag. 36, Cluj-Napoca,14-17 may 2009.
149. M. Rusu, L. Krucz, C. Cenan, Gh. Sebestyen, T. Nicoara, N. Todor, G. Saplacan -
Home Health Care Units in telehealth systems, 5th Conference of the Eastern
Mediterranean Region of the International Biometric Society EMR-IBS, EMR-IBS
2009, ISBN 978-605-60615-0-9, p. 127, 10th -14th of May 2009 Istanbul, TURCIA
150. N. Todor, Ioana Brie, V. Foris, Nagy Viorica, M. Rusu, G. Saplacan: Evaluation
index for DNA lesions in comet assay, 5th Conference of the Eastern Mediterranean
Region of the International Biometric Society EMR-IBS, EMR-IBS 2009, ISBN 978-605-
60615-0-9, p. 256, 10th -14th of May 2009, Istanbul, TURCIA
151. Mircea Rusu, Gavril Saplacan, Gheorghe Sebestyen, Calin Cenan, Lorand Krucz,
Timotei Nicoara, Nicolae Todor: Distributed e-Health System with Smart Self-care
Units, ICCP 2009 Cluj-Napoca, ROMANIA
2010
152. T. Ciprian, S. Olga, P. Teodora, E. Fischer-Fodor, D. Rus Ciuca, B. Pintea, O.
Mosteanu, S. Susman, A. Irimie, G. Kacso: Arsenic trioxide sensitizes hepatocellular
carcinoma cells to conventional chemotherapy. Abstract Book page 49, Medicalis
2010- The 11th International Congress for Medical Students and Young Doctors, Cluj
Napoca, 13-16 May 2010.
153. G. Chereches, C. Tatomir, D. Daicoviciu, I.D.Postescu : Antioxidant Effects of A
Grape Seed Extract (GSE) ; The Pathobiology and Molecular Biology of Tumors,
International Conference, 28-30 apr.2010, Cluj-Napoca, Romania.
154. P. Virag, E. Fischer-Fodor, M. Perde-Schrepler, I. Brie, C. Tatomir. Cytotoxicity
and cytogenetic features of oxaliplatin resistant colorectal cancer cell line, Biology
and Therapy of Cancer Cell, “Prof. Dr. Ion Chiricuta” Oncology Institute International
Conference, First Conference of the Romanian Division of IAP (International Academy
75
of Pathology): “The Pathobiology and Molecular Biology of Tumors”, Abstracts book,
2, supple, 2010, 31-32.
155. I-C. Brie, V. Nagy, P. Virag, M. Perde-Schrepler, E. Fischer-Fodor, V. Foris, N.
Todor. Prediciton of clinical outcome in patients with cervix carcinoma by the pre-
therapeutic evaluation of DNA lesions, Biology and Therapy of Cancer Cell, “Prof. Dr.
Ion Chiricuta” Oncology Institute International Conference, First Conference of the
Romanian Division of IAP (International Academy of Pathology): “The Pathobiology
and Molecular Biology of Tumors”, Abstracts book, 2, supple, 2010, 32.
156. C. Tomuleasa, O. Soritau, T. Pop, E. Fischer-Fodor, B. Pintea, P. Virag, G. Kacso,
M. Acalovschi, A. Irimie. Arsenic trioxide sensitizes cancer stem cells to conventional
chemotherapy – a differentiation therapy model for hepatocellular carcinoma,
Biology and Therapy of Cancer Cell, “Prof. Dr. Ion Chiricuta” Oncology Institute
International Conference, First Conference of the Romanian Division of IAP
(International Academy of Pathology): “The Pathobiology and Molecular Biology of
Tumors”, Abstracts book, 2, supple, 2010, 45-46.
157. E. Fischer-Fodor, O. Soritau, P. Virag, R. Buiga, D. Pelau, C. Lisencu, O. Barbos,
N. Miklasova, Y. Schiffenbauer, A. Irimie. A static cytometry evaluation of the ex vivo
tumoral chemosensitivity to platinum-based drugs, Biology and Therapy of Cancer
Cell, “Prof. Dr. Ion Chiricuta” Oncology Institute International Conference, First
Conference of the Romanian Division of IAP (International Academy of Pathology):
“The Pathobiology and Molecular Biology of Tumors”, Abstracts book, 2, supple,
2010, 49-50.
158. C. Tomuleasa, O. Soritau, I. Brie, E. Fischer-Fodor, M. Perde-Schrepler, P. Virag,
V. Cernea, G. Kacso. Mesenchymal stem cell irradiation in culture engages
differential effect of hyperfractionated radiotherapy for head and neck cancers,
Medicalis, International Congress for Medical Students and Young Doctors, 13-16
May, Cluj-Napoca, Abstract book, 2010, 64.
159. T. A. Pop, C.I. Tomuleasa, O. Mosteanu, O. Soritau, B. Pintea, M. Achalovschi:
Efectul chimioterapiei, in vitro, cu trioxid de arsen, cisplatin/interferon alfa
76
2b/doxorubicina/capecitabina asupra hepatocarcinomului, Journal of
Gastrointestinal and Liver Diseases, Vol. 19, suppl 1, Al XXX-lea Simpozion national de
gastroenterologie, hepatologie si endoscopie digestiva, 2010, 165
Reprezentant legal
Institutul Oncologic “Prof Dr I.Chiricuta”
Manager
Conf.Dr.Alexandru Irimie
Director cercetare - dezvoltare
Sef lucrari . Dr. Ioana Neagoe
77
Anexa 5.3. Număr de modele, normative, proceduri
1x 5 = 5 pct
2005
1. Magdalena Patruleasa, Daniela Coza, Carmen Popescu, Adela Ratiu – Editia in limba romana a
Clasificarii Internationale a Maladiilor pentru Oncologie – Editia a treia – Publicatie a
Organizatiei Mondiale a Sanatatii si Ministerului sanatatii publice
Reprezentant legal
Institutul Oncologic “Prof Dr I.Chiricuta”
Manager
Conf.Dr.Alexandru Irimie
Director cercetare - dezvoltare
Sef lucrari . Dr. Ioana Neagoe
i ; i I i I i r
E i | | I i I i Ii i - - ! - ! I I i i - i - i
3 i ' l i : i : : i : 1 . | i l
r t _ : _ t , t t 1 1 1
i 3 i i ' I r ' t ii l i ' i t l l
r r r r r r l _ ] , _ L
t i 1 : t : t : t : t 1
l a l l - i i i I
: _ . : _ t - I 1 t 1 t I
n i i . t . l l - t - t . l
t l t 1 1 r 1 1 l
- t - i _ i _ i i - i - i : i _ i
3
. i - . i
_ 1 _ t t l
_ : _ : - i - l
- 1_ l _ - ! , l - -
I I _ :
- r ; : ; ; ; l
i i ii i I
iJi
;IT
T3
iR
I
B
f,!iE
E
A
I
3
i 3 i d E
i - i -
t f I2
:
Ea6
g
{
i t - - - - i - i t t l
i t - - " . i . t t i
, ^ 1 1 . " t " " - -i 1 : i " . i i i o i : : : : l
i . . i . . i t l " - t - - - - l
i t . i . -
i . , i " ; r ' i ; . ; i i l : i ; i ; : i i
_ _ l ' : _ : _ _ _ _ !
i i i i i = i , i .
. - : - - - - - , - l- t - . . t 1 - - r - - F - r i F
, _ i _ _ . - _ _ l _ _ _ 1 _ _ _ r _ , , - _ _ _ : _ _
- i - - _ - ; - i - - - i ; a - i : - : a ; ; - i - - :
1 t
1 l
i
I
6
I
;
; - i - - , , . - - ' - - i .
: i " : e : i Q : i 9 i 9 9 9 ? 9 e o 1 : " , : 9 i :
- i " . i . 6 i . i . " , _ " . " . . - i . i "
i i i t t t i ,i i l i i t i i
l - - - . i - .
i t l
r i i i iI I . t I i i i
! r ! i l l r I t t l
" . i " . " r " - i - i - - i " i . " . " J i " ; ; ; i ; t ; t ; li ; i J ; ; ; , i l , . i i - - i i ; i ; F ; ; ; ; ; ; ; ; ; l i i J i
- , ! - t . - - - l . t - t - . i - i - " - - , i . - - - . 1 - t - t - l
t l t t t t t ! t 'i i i t i t ii , i , , i - - - - - - - - - i - i
; i ; i ; i i ; i ; i ; i . , J i n ; l d d ; ; J " i ; i i ; ; i ; l i n
. i " . i - - i - i . i . . i " . i " . . - . 1 . . i " . - i - i " .
t t ii t i i i i t t i
_ L t - l _ t 1 1 1 1 L 1 ! _ _ : _ _ _ t _ : , 1 I- - i - - - t - - - t . - t - - - - - J - - - - - - i - l " l
" i - . t - - - | . | - | - l I - i - " - " . t . - - - . i - . i " l
i i i i t i i ,,. _ _ _ I _ _ _ i _ I _ I _ - ' 'i . t . t " J , . t " t " i " . i . . t - - - - i A - i " . . i . i " . l
i - . - " i i ' i i
- i t l 1 1 1 1 1 1 t _ _ _ _ ! _ _ i _ _ _ 1 , : I It . i . i - - i " l . i " . " " . J J . 1 " . " . i - . il ; i n l i ; ; i ; l ; i ; ; " : " : . i J ; ; l ; ; n ; i ; . i i
: . i - i , " i " . i , , - . , - - , , i " " i
" I - - - r . . . - - l - r -
r r : ' - - I - - I
i r i i l , ii i i l i l
i i . i - i ; - ; i : i - - - : - - - _ _ i - . . ,
" : ' i i , : - : , . r i
, i i l l t l. i i l i i l
i i i i i i t i i l
t t l l i t t t l
l t t t t i r ii i i i t i li i t i t l
i i t t t t t li , i - i - i ,
t ! i t i t l i I r i _ i _ i - l i
1 _ _ _ . t _ : _ _ _ . : _ _ _ - , f
l r f r r r r r _ : _ ] _ L _ 1 _
i i - - i - _
,
l t _ l _ t _ l _ l r r l l I l l r r r r
, j : d . ; i : : , 5 i 1 . " i ? ' 1 - l ; i ' . i . 5 t - :
I
l
L
IIIII
!i;
ga
c
Ia;ni 5
5 .
Tl t t t t lr i i i i
i i l t l
_ 1 I I l _ t _ i _ ] -l i " - i - i - i - l
r r _ t _ : _ 1 _ 1 _ 1 ,
1 _ t _ _ _ l _ 1 _ f _ f _ r -
1 r _ _ t _ : _ l _ i _ t _
I I r r 1 : _ _ ! _
_1_ i_ _ _. t _ t _ i - t - t
- i - i i . _ - i - i i : i _ i
9 { 9 1 9 9 9 1 9 t 9 1 9 1 9 1 !
{
I
i i i i I i i ai i i i i i i ;
I I ; i ; ; i i l ; i ; i ; i ; n n l ;
3 t | - t . - t - t " t - r - . t . . t -
t € . t . l . t - - t . t - i . - l - 1 .t 3 I t - l - l
i i l l - l " l - i " - i " t . l " . l . t .
i a r - i t " l - i
l t t I I I I l _ t _ : _ i _ : _ i _
n l | | i t l t i i .
l S t i | | I I I I i r "
w!p@M
Bilant - COD Ol - BILANT
TUL ONCOLOGIC .'PTof, DT, I.CHIRICUTA'' CLUJ-NAPOCA
2009
DaoalauI - furrxuldr r\dyurli!E
c ulmeaza a fi ncasat€ intr-o perloada mai mrca
INSTIT
Luna Raportar i i ; DECE14BER
http://ms.softeh.ro:88E8/oadFormulaxAsP.aspx
,t(apoftan lJUgeI Nnruslgru1 Danaldur - rurtrrud ^dpurldE
http://ms.soft eh.ro:8888/aILoadFormularASP.aspx
t
(.t,232+234+409+4!1:
omerclale/ avansur si alte de@ntari
.+411S+413+413+425+4282+4611+473**+2t 2p43.587 11583672
(d.232+234+409+4It+4113+413+413+461149113961): din Gre22 2843587 11583672
t32+234+409) 22,r 0
l+* + 431 ** + 4 4 24 + 442A+' + 444*+ + 4 4 6* r + 4 4a2
t664+4665+4669+431*++482'*-497) d a crel 23 0 0
4669-497)
ec L consol dat {ct,463 +464+465 +4664+46 6 5+0
u fonduriextern€ neramblBabies fondur de la
505+4507+4511+4513+4515+4531+4541+
t+4561+4563+4571+4572+4573+4531+4533+25
misla Euooeana (ct,4501+4503+4505+45071 26 0
469)
s.ud acordate (ct,2671+26t2+2673+26J 5+26J6
82+4533+4634+4635+4586+4687+4633+4539+27 0
3, t(ct.sos+595) 31 0 0
32
(ct,5l0+5121+5125+55201+5211+5212+52'523+5291+5292+529:5582+5591+5601+56(5142+5743+5744) din
a, alte valon, avansurldetrezorere31+5141+5151+5153+5161r5171+5187++ 5222 + 523 + 525 | + 5252+ 5253 + 526 + 527 +-5294+5299+5311+532+542+550 ta 557+5531++ 561 + 562+ 57 11 + 5J 12+ 57 13+ 57 14 + 57 47 +
2p39F49 469224
+ 5222 + 5642+ 5 t 14 + 57 4 4l 34 0
contu la hstitutli de cre{+5124+5125+5131+513t5171+5172+51S7+53141
llt, ca*, avansurlde hso€r e (ci.550+s112+s121r+5141+5142+5151+5152+5153+5161+5162+5411+5412+542+5533+5592+5601+5602) 35 1403362
+5602) 0 0
- 373S3S5
{cr.5126+5127+s187+5r01+s202+5203+5241+5242+s243)
6, 1 l 42 24045 8 5 1 8
J . TOTAL ACTWE CUREN 45
8, r5) 84SOO9t3 . 160m6593
30.01 .2010
,Raportai Buget Ministemll Sanatalii - Folmular Rapofiare
http://ms.softehro : 8888/aI-oadFormularASP.aspx
Page 3 of4
DATORIT 50
DATORII NECIIRENTE - sume ceumeaza afi plautedupa o perioada51
ceumeaza afi plante dupa operioada mai
101+403+4042+405+4622+509) d n care:52 7530
!4n3+4042+445+4622) 53
2.1662+1672+168-169)
l!ng (ct.1612+1622+1632+1642+1652+1661+
3. 0
:NIE (rd,s2+54+ss) 53 : . "i rrpo'
neceurmeaza afi platit€ Intr-o perloada de
1 (ct,401+403+4041+40
+5128) din Gre:
;+408+419+4621+471+481+482+483+269+509+60
dsu (ct, 401+403+4041+405+408+419+4621)61 9036498
0
2,
+46J2+4673+4674+4t
| 4 423 + 4 428 + 44 4 + 4 46 + 448 1 + 4 55 5 + 467 1 +
,5+4679+473+6i4s2) did cae:62 671919 1331166
(d- 43t+437+4423+4463 671919 1331166
1+437) $7534
i dln iondurl €xten€ nerambuEabrl€ (ct.4sss) 0
3, (d,4502+4s04+4506{
+4546+4552+4554+4:
fondurr externe neEmbursable sl fondu
:atre alte organlsme lntematonale
| 5t2+ 45 14 + 4 5 16 + 4 521 + 4 522 + 4 532+ 4 542 + 4544
i4+4584+453s+459+473+462+475)
0
759+462)
(ct.5186+5191+5192{
scurt - sume ce urmea4 a fi platite intr-o
t193+5194+5195+5196+s197+5198)70
0
5,
ung, sumeft urmeaza a f plalit€ in c!6u
1641+1551+1551+1662+1671+163,169)
o
6. ] saldill€ anqajatilor
+427r+428,, ]j2 | 1197917 968109
30.01 .2010
, .Raporta.ri
I
i Buget Mitri sanatata - f omular Kapo are
.+4213+429+434)0
)naj, bu6e (ct. 422+424+429) 73,1 0 0
8, ) 0
9_ 75 0 0
10,(rd.60+62+65+70+71
IE
72+73+ 14+?5) rxxxlawTOTAL DATORII (rd, 5l r78)
12,ACTIVE NEIE EIAI TOTAL\cnvE - TOTAL DATORII esal CAPTALURI PRoPRll
30
c.
1 (ct, 100+101+102+10:
+137+1391+1392+131
f 104+105+106+131+132+133+134+135+136
r+1394+1396+1399)
68419682 124492495
2, 85 9401831 I1726995
3, 0
dercltiului (d121 - sld creditor) 2322525 12112152
5. *r.mulul (d, 121 - so d debrtor) 88 0 0
6. PRII (rd,M+85-86+87-88)
r//ms.softeh.ro:8888/
(,<W':t--:-:,-al
ael.l!,t r) - \ . itre";,A*V\ \\
, AV\\\\
Vf\-.,\ftilffi
ormularASP.aspx 30.01.201http
ORJEPLATT
Cod de
Cod IBp6titol
D e h I
)Iry-IfoR r
L
AN
IE PLATA
-'fisr
r ' . F t: t I PLATlrl I:--"pt*lti;....-......"-...LJL ONCOLOCIC CLUI
4)4 t t t ) | eo*o
)6CLUJNAPOCA
..-.-- coi"r Brclilffiwffiffiffiffiffiilm
RO4OTREZ265001xxx006757 | I KxzKUbu
* t'lLri"ipiut Clul I'luPo"a
BENEFICIAR
Cod IBAN
17128123 Codul BIcNORMAL
!riourir&nsf.rurui T-l f-lRO73TR.EZo5otxxxoor865 lTRrzRoBU
LA i-tiwvunic,prutBucuesti
[5Ir;RE ARr 5 Pcr 7
D . i r c n ' r e F ' | / 2 3 u t t z o t u / l l ! - t t t . E 9 -| | ,i ! n ;. -' ..::'.| , . 7 l i l '
. - .V ! ] i * , 1 Y - r " '-s..rirGZ&fiftr"^fir,i sr;.etr{- v
iEn, , roor
)